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PREPARATION OF BIOCOMPOSITES USING SPRAY DRYER AND 
THEIR APPLICATIONS IN DRUG DELIVERY SYSTEMS 
SUMMARY 
Biodegradable and biocompatible polymers have been widely used in drug delivery 
systems with an increasing interest. The main reason to drive biopolymers for top 
material for drug delivery applications is after drug depletion, the carrier degraded in 
the body to form products that are easily resorbed or eliminated. On the other hand, 
the unwanted adverse effects have to be minimized and therapeutic improvement has 
to be maximized at the same time for an effective and useful drug delivery tool. The 
only way to obtain improved therapy is that creating very effective drug release in 
the body and bio-based polymers could provide these vital necessities. Because of 
these reasons, biopolymers are preferred for drug delivery systems. 
The biodegradable polymers are a new class of controlled release polymers 
developed for the interstitial delivery of drugs to their target site in human body over 
periods ranging from days to years. These polymers can release molecules of any 
size in a predictable fashion. Their degradation products are non-cytotoxic and 
biocompatible. The only way  to  obtain  improved  therapy  is  that  creating  very 
effective drug  release  in  the body and bio-based polymers could provide  these 
vital necessities. Because  of  these  reasons,  biopolymers  are  preferred  for  drug  
delivery systems. 
Controlled drug delivery systems have become increasingly attractive options for 
inhalation therapies. A large number of carrier systems have been developed and 
investigated as potential controlled drug delivery formulations to the lung, including 
drug loaded lipid and polymer based particles. However, there are some 
extraordinary specifications should have for a drug delivery material. First of all, 
polymers which are used in a drug delivery system, it has to be biodegradable and 
biocompatible. For example, polycaprolactone, polyethylene glycol , polylactic acid, 
chitosan, chitin, and polyglycolic acid and their blends or copolymers are widely 
used for drug delivery systems because of controllable particle diameter, particle size 
distribution, and biodegradation rate in human body. 
Spray drying is transformation of material from solution state to powder form by 
spraying feed into a hot air medium. The production of dried particles from a liquid 
feed in a single processing step makes spray drying a unique and important process. 
Since then, a tremendous development of the spray drying process with the 
refinement in the hardware and equipment conﬁguration and improved understanding 
of fluid dynamics has made it versatile technique operational in diverse industrial 
fields. Spray drying is widely used for the drying of heat-sensitive foods, 
pharmaceuticals, and other substances mainly due to rapid solvent evaporation and 
homogeneous particle size distribution. At last decade, spray dryers have been 
preferred for pharmaceutical industry by combining drug delivery systems with 
micro-particle uniform distributed polymeric materials. Furthermore, amorphous 
solid dispersions, soluble complexes, encapsulated systems, solid self-emulsifying 
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systems and nano-dispersions of poorly soluble drugs prepared by spray drying are 
primary solubilization strategies.  
The present work concerns the preparation and characterizations of biodegradable, 
biocompatible biopolymer based composites and obtain uniform particle size 
distribution at the same time. For achieving of the goal our study, we used 
polycaprolactone, polyethylene glycol, chitosan, casein, and sodium alginate to 
prepare drug delivery system and spray dryer will be our tool to obtain microspheres. 
Triple mixture of the polymers are used such as polycaprolactone-polyethylene 
glycol-chitosan, polycaprolactone-polyethylene glycol-casein, and polycaprolactone-
polyethylene glycol-sodium alginate. First of all, we are evaluated effects of spray 
drying conditions and composition of the microencapsulating formulation. Secondly, 
the most uniform distributed particle size microsphere are selected and drug active 
ingredient is loaded to it. L-ascorbic acid is an active ingredient for the study. After 
that, drug encapsulation and drug release studies are performed. Drug release 
experiments are maintained at different pH solutions (pH 2.5, 7.4, and 9.6). Finally, 
drug release kinetics are determined by widely used equations to describe the 
degradation kinetics; Zero-order, First-order, Higuchi, Hixson-Crowell, and 
Korsmeyer-Peppas. Furthermore, L-ascorbic acid release mechanism from 
microspheres is also determined. Release profiles of three microspheres produced are 
obeyed to previously developed kinetic models to perform possible release 
mechanisms; The Korsmeyer–Peppas model is the best described each release 
scenario. 
Encapsulation and drug release ratio are easily adjusted by changing structure of 
microspheres. Particularly, release behavior of microspheres are changed by 
replacing biopolymers in the drug structure. By this way, released L-ascorbic acid 
ratio in different release mediums are adjusted.   
The main reason of using of ternary polymer mixture is that to obtain best  
performance from a drug material because these polymer has some superior features 
but they are not enough separately. The importance of the study is producing of a 
stable and effective drug encapsulation system using  ternary polymer mixture by  
spray dryer Our study is proposed as an alternative or adjuvants for controlling 
release of L-ascorbic acid. By this way, we can achieved higher drug loading and 
drug release efficiency in our study.  
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PÜSKÜRTMELİ KURUTUCU İLE BİYOKOMPOZİTLERİN 
HAZIRLANMASI VE İLAÇ TAŞINIM SİSTEMLERİNDE KULLANIMI 
ÖZET 
Biyoteknolojik uygulamaların önemli bir bölümünü oluşturan biyomalzeme üretimi 
günümüz mühendislik teknolojisinin güncel konularından biridir. Üretilen 
biyomalzemelerin biyouyumlu olması, toksik ve kanserojen olmaması, kimyasal 
açıdan kararlı olması, yeterli mekanik dayanıma sahip olması istenen 
özelliklerdendir. Seramik, metalik, polimerik ve kompozit malzemeler genellikle 
biyomalzeme olarak kullanılmaktadır.  
Biyopolimerler, toksik etki yaratmadan bozulabilmeleri ve biyouyumlu olabilmeleri 
bakımından ilaçtan yapay organlara birçok alanda kullanılmaktadır. İlaç taşınım 
sistemlerinde biyopolimerlerin tercih edilme sebeplerine yukarıda bahsi geçen 
özelliklerin yanı sıra mekanik ve fiziksel açıdan kolay işlenebilir ve dayanımlarının 
ayarlanabilir olmaları da eklenebilmektedir. Kullanıldıkları biyolojik alanlara örnek 
olarak ilaç salım sistemleri, doku ve organ nakilleri ve ortopedik uygulamalar 
verilebilmektedir. Biyopolimerlerin kullanım alanlarına doku mühendisliği 
uygulamaları, tarımsal uygulamalar, ambalaj sektörü, medikal uygulamalar ve 
kontrollü ilaç salınım sistemleri örnek olarak verilebilir. Biyopolimerlerin ilaç 
kapsülasyon, vücutta taşınım ve kontrollü salınması ile ilgili sistemlerde 
kullanılmalarının sebepleri, ilacı taşıyıp bıraktıktan sonra kolaylıkla vücutta absorbe 
edilebilmeleri ve böylece vücuttan hızlı bir şekilde atılabilmeleridir. Ayrıca, vücutta 
bozunmalarıyla ortaya çıkan bileşenlerin toksik etkisi yoktur. Bunun yanı sıra fazla 
dozda alımdan kaynaklanan ilaç yan etkileri azaltılırken, ilacı etkinlik bölgesine 
taşıyarak terapötik etkisinin arttırılması oldukça önemli bir konudur. Ayrıca, 
özellikle hassas ilaç etken maddelerin bozunmadan etkinlik bölgesine taşınabilmesi 
amacıyla enkapsülasyonu ilaç taşıma sistemlerinin avantajları arasında sayılabilir.  
İlaç taşıma sistemi, bir etken maddenin ilaç salınım süresinin  ve hızının 
ayarlanabilmesini sağlayan, böylece ilaç yan etkisini minimize edebilmemize 
yardımcı olan araç veya formülasyon olarak tanımlanabilir. İlaç taşıma sistemleri ve 
artan ilgilerinin sebebi düşük doz alımında bile vücutta yeterli etkiyi 
sağlayabilmeleridir. Ayrıca ilaç plazma konsantrasyonunun istenen süre ve 
kararlılıkta olmasına da yardımcı olurlar. Genel olarak ilaç taşıma sistemlerinde etkin 
salınım veriminin sağlanabilmesi ve bahsi geçen üstün özelliklerin elde edilebilmesi 
için tek bir polimer değil de polimer karışımları kullanılır.   
İlaç taşıma sistemi olarak kullanılabilmesi için herhangi bir polimerin belirli üstün 
yapısal özelliklerinin bulunması gerekmektedir. İlk olarak, kullanılacak olan polimer 
türlerinin biyobozunur ve biyouyumlu olmaları gerekmektedir. Bu tür polimerlere 
örnek olarak polikaprolakton, polietilen glikol, polilaktik asit, kitosan, kitin ve 
poliglikolik asit gibi polimerler ve bunların karışımlarından yada kopolimerlerinden 
oluşan malzemeler yaygın olarak kullanılmaktadır. İkinci diğer en önemli özellik ise 
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ilaç kapsül maddelerinin partikül boyutlarının kontrol edilebilir ve yoğunluklarının 
ayarlanabilir olmasıdır ki vücutta her organ ve doku için istenen özellikler 
değişebilmektedir. 
Püskürtmeli kurutucular malzemeleri akışkan formdan kuru tanecikli forma 
dönüştüren ve bunu püskürttüğü akışkanı sıcak bir gaz ortamında kurutan yapılardır. 
Püskürtmeli kurutucular kurutma işlemini çok hızlı yaptıklarından ve homojen 
partikül boyut dağılımına sahip malzemeler üretilmesine olanak tanıdığından dolayı 
birçok farklı alanda kullanılabilmektedir. Kurutulacak maddelerin sıcak havaya 
nispeten daha kısa süre maruz kalması ve akışkanlaştırılan havanın ısı transferi 
kapasitesinin artmasıyla daha düşük sıcaklıklarda kurutma sağlanabilmesi 
dolayısıyla, ısıya hassas gıdaların ve ilaçların üretilmesinde püskürtmeli kurutucular 
sıklıkla kullanılmaktadır. Özellikle de son yıllarda mikropartikül temelli ilaç taşıma 
sistemlerinin geliştirilmesinde tercih edilen bir yöntem olmuştur. Ayrıca püskürtmeli 
kurutucular ile suda çözünürlüğü düşük olan ilaç etken maddelerinin dahi 
kapsülasyonu yapılabilmektedir.  
Sağlıklı bir gelişim, diş, kemik ve deri için vazgeçilmez bir bileşen olan C vitamini 
olarak da adlandırılan L-askorbik asit (3-keto-L-gulofuranolaktan); demirin 
absorblanması, kolajen sentezi, kan damarlarının yapısal gücünün sürdürülmesi, 
bazı aminoasitlerin metabolizmasında ve adrenal bezlerin hormon sentezi ve 
salgılaması gibi metabolik fonksiyonlarda görev alan karbonhidrat benzeri bir 
kimyasal maddedir. Ancak L-askorbik asit kolay okside olabilen ve bozulabilen bir 
malzemedir. Oksijen varlığı, sıcaklık yükselmesi, güneş ışığı ve ultraviyole ışıklara 
maruz kalma, bakır ve demir gibi ağır metallerin varlığı, güçlü asit ve alkali koşullar 
gibi durumlarda bu oksidasyonun derecesi artmaktadır. Çalışmamızda L-askorbik 
asidin bozulmadan ve stabil kalarak enkapsüle edilmesi amaçlanmıştır. 
Bu çalışmanın amacı, polikaprolakton, polietilen glikol, kitosan, kazein ve sodyum 
aljinat polimerlerinin mikrokürecik yapısında hazırlanması ve ilaç taşıma sistemi 
olarak kullanımının incelenmesidir. Bu sayede biyobozunma, biyouyumluluk ve 
kapsülün stabilitesi gibi problemler de tekli değil de üçlü polimer kompoziti ile 
aşılabilmesi beklenmektedir. Bu amaçla ilk aşamada üçlü polimer karışımından 
oluşan çözeltiler püskürtmeli kurutucuda kurutularak mikrokürecikler üretilmiştir. 
Püskürtmeli kurutma işleminde giriş sıcaklığı ve besleme debisi parametrelerinin 
partikül boyutu, partikül verimi ve yüzey alanı üzerine etkisi incelenmiştir. Sonraki 
aşamada, üretilen mikroküreciklere ilaç yüklemesi için uygun koşullar belirlenmiştir. 
İlaç etken maddesi olan L-askorbik asit kullanılmıştır. Son olarak ilaç yüklü 
mikroküreciklerin asidik, nötral ve alkali ortamlarda ilaç salınım özellikleri 
incelenmiş ve ilaç salınım kinetiği parametreleri belirlenmiştir. 
İlk aşamada, polimerik mikrokürecikler elde etmek için üçlü polimer karışımı 
püskürtmeli kurutucu ile kurutulmuştur. Püskürtmeli kurutucuda çözeltinin besleme 
debisinin ve kurutma havası sıcaklığının değiştirilerek mikroaprtiküller morfolojisi 
üzerindeki etkisi incelenmiştir. En etkili kurutma parametreleri (sıcaklık ve debisi) 
kullanılan polimer karışımının türüne göre değişmiştir. Çözelti besleme debisi ve 
kurutma havası sıcaklığı değiştirilerek elde edilen mikropartiküllerin SEM ve 
partikül boyut analizleri yapılmıştır. Üretilen mikrokürecik termogravimetrik analiz 
ile yapısal olarak incelenmiştir.  
Çalışmanın ikinci aşaması ilaç yüklü partiküllerin üretilmesidir. Dolaylı ilaç yükleme 
metodu ile seçilen mikroküreciklere L-askorbik asit yüklemesi yapılmıştır. Yüklenen 
xxv 
 
ilaç miktarları UV analiz ile belirlenmiştir. İlaç yükleme koşullarında mikrokürecik 
miktarı ve L-askorbik asit çözeltisi derişimleri değiştirilmiştir.   
Çalışmanın son aşamasında ise L-askorbik asit yüklü mikroküreciklerin farklı pH 
ortamlarında kontrollü ilaç salınımı incelenmiştir. L-askorbik asit yüklü partiküllerin 
üç farklı pH ortamında da sekiz saat süresince ilaç salınımını deneyleri 
gerçekleştirilmiştir. En yüksek ilaç salınım oranı 2 saat içerisinde % 93 ile pH 2.8 
ortamında elde edilmiştir. İlaç salınım miktarları mikrokürecik yapısına göre 
değişmektedir. Ayrıca yapılan deneyler göstermiştir ki mikrokürecik yapısı 
değiştirilerek ilacın en etkin olacağı salınım ortamı da manipüle edilebilmektedir. 
Böylece L-askorbik asit yüklü ilaçların insan vücudunda istenilen salınım süresi ve 
ilaç salınım noktaları elde edilmesine olanak sağlanabilmektedir.  
Çalışmalarımız süresince elde edilen veriler ışığında söylenebilir ki ilaç 
enkapsülasyon malzemeleri seçiminde tek polimere bağlı kalınmasındansa birden 
fazla polimer karışımından oluşan bir yapı kullanmak avantaj sağlamaktadır. Bu 
sayede ilaç yükleme ve ilaç salınım oranları ayarlanabilmekte/değiştirilebilmektedir. 
İlacın istenilen salınım ortamında daha etken olması da sağlanabilmektedir. Ayrıca 
püskürtmeli kurutucu kullanılarak mikrokürecik eldesi de daha homojen ve düşük 
partikül boyut dağılımına sahip yapılar elde etmemize olanak vermiştir. Böylece 
etkili enkapsüle sistemleri üretmemiz kolaylaşmıştır.  
L-askorbik asit gibi kolayca çevresel etkenlerden dolayı yapısal bozulmaya uğrayan 
ancak hayati öneme sahip ilaç etken maddelerinin kaplanması ve taşınmasında 
çalışmalarımız esnasında geliştirdiğimiz yöntemlerin kullanılabilir olduğu 
görülmektedir. Çalışmamız verimli ve stabil ilaç sistemlerinin elde edilmesine 
yardımcı olabilecek bir yol önermektedir.   
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1. INTRODUCTION 
Nowadays,  pharmaceutical  industry  has  been  focused  on  some  specific  
biodegradable and biocompatible polymers which are polycaprolactone  (PCL), 
polyethylene glycol  (PEG), chitosan (CH), polyglycolic acid (PGA), polylactic acid 
(PLA), sodium alginate (SA), and chitin [1]. Biodegradable and biocompatible 
polymers have many advantages for drug delivery systems such as porous surface, 
encapsulation efficiency, high drug release ratio, high stability, low side effects, and 
good drug-encapsulation material interaction. Drug delivery research aims to 
conveniently administer complex drugs to the target tissue in the biological system in 
a more stable and reproducible controlled way so that it would achieve higher 
activity at a minimal dose for prolonged period at the site devoid of side effects.  
Entrapment  of  a  drug  into  a  polymeric  system  may  protect  the  drug  from 
inactivation  and  help  to  retain  its  activity  for  prolonged  durations, decrease its 
toxicity, dosing frequency and offers flexibility in administration [2].   
Particulate drug carriers can act as delivery vehicles for drugs through various routes 
of administration [3]. On the other hand, the undesirable adverse effects have  to    be  
minimized and therapeutic  improvement has  to  be maximized at  the  same time  
for  an  effective  and  useful  drug  delivery tool [4-7]. The only way to obtain 
improved therapy is that creating very effective drug release in the body and bio-
based polymers could provide these vital necessities. Because of these reasons, 
biodegradable polymers are preferred for drug delivery systems.  
Drug encapsulation in colloidal delivery systems is an efﬁcient approach to improve 
the pharmacokinetics of hydrophilic drugs [8]. These carriers encompass a broad 
range of dispersion systems ranging from submicron emulsions to colloidal particles, 
such as biopolymers (PCL, PEG, CH, CS, SA, and starch)  aiming  to  protect  the  
drug against degradation, sustain drug release, increase patient comfort by  avoiding  
repetitive  bolus  injections  or  the  use  of  perfusion pumps and reduce side effects 
[9-11].  
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It is always a fact that performance of a drug delivery system is about encapsulation 
and release efficiency. One of the basic requirements for the controlled and balanced 
release of the medicament in the body is its ideal spherical shape of polymeric 
particles and narrow distribution of their sizes. The size and shape of the particles 
play key role in their adhesion and interaction with the cell [12]. Another important 
issue for drug delivery systems is that stability at outside of the human body and 
sufficient degradation of drugs inside of human body. To overcome this problem, 
mixture of biopolymer for drug delivery systems could be an enormous alternative 
because biodegradation rate is easily adjustable by blends of polymers. At these view 
of points, preparing of a drug easily biodegradable, biocompatible inside the body 
and stable outside the body is the main problem and most important goal for 
pharmaceutical industry.  
L-ascorbic acid, commonly called vitamin C, is a highly abundant and essential 
metabolite for plants and animals.  It  is  an  important  dietary  supplement  for  
some  animals,  such  as primates  and  humans,  which  lack  the  capacity  to  
synthesize  L-ascorbic  acid.  It has attracted  considerable  attention  from  the  
scientific  community  due  to  their  numerous beneficial effects for human health, 
which include antioxidant and immune booster effects [13].  Unfortunately,  while  
L-ascorbic  acid  provides  beneﬁcial  therapeutic  effects,  its stability  also  easily  
effected temperature, sun-light and O2. Thus, encapsulation of L-ascorbic acid would 
provide a stable and highly effective drug [12].   
Spray drying is known to be a convenient one-step process for the continuous 
conversion of  liquid  formulations  into  dry  particulates, which  is well-established  
in many  relevant branches such as the chemical, food or pharmaceutical industry, 
due to the high flexibility to manipulate particle properties (e.g. size and 
morphology) [14]. It  is  the  process  of  contacting  an  atomized  stream  to  be  
dried with  a  gas stream that  is at a higher temperature than the  liquid stream. The 
higher temperature of the gas stream causes evaporation of the liquid from the 
droplets, forming particles. It results in microspheres with good quality, low fluid 
activity (water etc.), easier handling, and storage [15-19]. Equipment is readily 
available and production costs are lower than most other methods. Another 
advantage of spray  drying  is  that  it  is  possible  to  control  particle  size  and  
morphology  by  varying process  parameters  and  formulation.  This is of great 
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importance for the preparation of powders for drug encapsulation. Recently, the use 
of this process to manufacture hollow, micron and sub-micron particles has also been 
demonstrated [15, 17]. Therefore, spray drying  can  be  considered  as  an interesting  
alternative  to  any  other  methods  for  the  preparation  of  amorphous  solid 
dispersions, soluble complexes, encapsulated systems, solid self-emulsifying systems 
and nano-dispersions of poorly soluble drugs [20-22].  
On the basis of these remarks, aim of our work is encapsulation of L-ascorbic acid in 
microspheres made by biocompatible and biodegradable polymers that are PCL, 
PEG, CH, CS, and SA. (PCL-PEG-CS) in order to obtain (i) production of effective 
and stable encapsulation material (ii) enhancing of encapsulation and (iii) increasing 
of drug release ratio simulated with different pH mediums. We used ternary polymer 
mixture to obtain best performance from an encapsulation material because a 
combination of these materials could achieve superior characteristics than each 
component individually and spray dryer was our tool to obtain microspheres. 
Another importance of the study was encapsulation of L-ascorbic acid, essential 
vitamin for humans. For achieving of the goal our study, we used PCL-PEG-CH, 
PCL-PEG-CS, and PCL-PEG-SA to prepare drug delivery systems. First, we 
evaluated effects of spray drying conditions and composition of the 
microencapsulating formulation.  Secondly, the uniform distributed particle sized 
microsphere was selected and drug was loaded to it. L-ascorbic acid is the active 
ingredient for the study. After that, drug encapsulation and drug release efficiencies 
were calculated and best drying conditions were determined. Drug release studies 
were accomplished at different pH mediums (2.8, 7.4, and 9.6). 
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2. SUMMARY OF LITERATURE 
2.1 Biopolymers for Drug Delivery Systems 
Polymers  and  polymer  based  materials  have  been  widely  used  for  biomedical 
applications, particularly drug delivery systems, artificial tissues, and prosthesis. The 
main reasons of highly preference of polymer on biomedical area are that higher 
elasticity and strength, biocompatibility and biodegradability, adjustable 
hydrophobicity and hydrophilicity, and porosity. Biocompatibility and 
biodegradability are the most important factors that affect a materials using area on 
biomedical applications. One of the main areas of usage of biodegradable polymers 
is related to their clinical applications, and knowledge of the toxicity of the products 
released during their biodegradation is certainly of great concern. In vitro 
degradation tests in simulated physiological solutions are a means of forecasting the 
interactions between body fluids and the biopolymer, and to study its stability and 
degradation rate. Biocompatibility  includes  interaction  between  human  cell  and  
drug,  toxicity  of  a drug; biodegradability means throwing easily of drug from the 
body [23].   
The basic principles for development of drug delivery systems are easily integration 
of active ingredient into drug, achieving of higher drug release ratios, and non-toxic 
effects of drug capsule to cells after its biodegradation. The last ten years, production 
of more effective, biocompatible, and biodegradable drug systems have been 
increasingly interest for pharmaceutical industry [24-29]. Nowadays, polyester based 
biopolymers are used for drug delivery and encapsulation systems and some 
examples of these polymers are polycaprolactone, polyethylene glycol, polylactic 
acid, polyglycolic acid, polyacrylic acid (PAA), poly(methyl methacrylate) 
(PMMA), chitosan, chitin, casein, alginate, and starch [29].  
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2.1.1 Polycaprolactone as an encapsulation agent 
PCL, a semi-crystalline linear aliphatic polyester approved by the US Food and Drug 
Administration (FDA), has attracted much attention to be used in the controlled drug 
delivery due to non-toxicity and low cost [30]. Besides, the degradation of 
polycaprolactone does not result in an acid environment and its degradation products 
can be solubilized by body fluids and removed by phagocytosis. PCL is prepared by 
the ring-opening polymerization of the cyclic monomer ɛ-caprolactone and structure 
of polymer chain is shown in Figure 2.1. 
 
Figure 2.1 : Polycaprolactone chain structure [27]. 
Some applications of PCL for biomedical area are surgical suture, bone and tissue 
engineering systems, and drug delivery systems with other bio-based polymers. In 
the past four decades, several studies have been published relating to the 
biocompatibility of sutures made from aliphatic polyesters [27]. A block copolymer 
of PCL with glycolide, offering reduced stiffness compared with pure polyglycolide, 
is being sold as a monofilament suture by Ethicon, Inc. (Somerville, NJ), under the 
trade name Monacryl [31]. 
Because of controllable biodegradability, easily shaped, and producible in different  
porous  size,  PCL  has  more  advantages  than  other  biopolymers  for biomedical 
applications [32]. Due to a higher permeability of PCL, it is blended with other 
polymers to improve stress, crack resistance, dyeability and control over release rate 
of drugs.  
Within the last decades, PCL polymers have been major area of interest to develop 
controlled delivery systems especially for peptides and proteins [27]. The matrix 
material of bioresorbable microparticles can be decomposed into non-toxic and low 
molecular weight species concomitant with release of the drug which are then 
metabolized or absorbed by the organism. It is no surprise that considerable research 
interest is now focused on the application of biodegradable microparticles for 
controlled drugs release. Among them, polycaprolactone is one of the more widely 
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utilized. The advantages of PCL include its high permeability to small drug 
molecules, and its negligible tendency to generate an acidic environment during 
degradation as compared to PLA and PGAs [33]. PCL microspheres can be prepared 
by several different methods and spray drying is common technique, which is 
reviewed by Freiberg and Zhu [34]. Uniform distributed microspheres and 
production of drugs with effective encapsulation ratio are easily achieved by this 
way.  
2.1.2 Polyethylene glycol as an encapsulation agent 
PEG is a bio-based polyether class polymer, although its monomer is toxic for 
human tissues. PEGs (in Figure 2.2) are known as compounds with widespread 
industrial and medical applications.  
 
Figure 2.2 : Polyethylene glycol chain structure [35]. 
Today,  it  is  an  indispensable material  for drug  industry  and  it  is  one  of  the  
first  polymers which  are  used  for  drug  delivery systems. The advantages of PEG  
than other polymers are  it can be easily  interacted active  ingredients  with  weak  
hydrogen  bonds  and  contributes  to  development  of stable drug delivery systems 
[35, 36]. Furthermore, PEG based copolymers play a crucial role as a biomedical 
material for biomedical applications, because of its biocompatibility, 
biodegradability, thermo-sensitivity and easy controlled characters [37].  
PEGylation (also often styled pegylation) is the process of both covalent and non-
covalent attachment or amalgamation of PEG polymer chains to molecules and 
macrostructures, such as a drug, therapeutic protein or vesicle, which is then 
described as PEGylated (pegylated) [38]. PEGylation is routinely achieved by 
incubation of a reactive derivative of PEG with the target molecule. The covalent 
attachment of PEG to a drug or therapeutic protein can "mask" the agent from the 
host's immune system (reduced immunogenicity and antigenicity), and increase the 
hydrodynamic size (size in solution) of the agent which prolongs its circulatory time 
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by reducing renal clearance. PEGylation can also provide water solubility to 
hydrophobic drugs and proteins. 
A common method of preventing the biological adhesion of proteins and cells is to 
coat the artificial surfaces with PEG polymers. This ability to generate protein-
resistant surfaces is often attributed to the fact that PEG chains are highly mobile and 
flexible as well as hydrated. Due to the high mobility of the surface-attached and 
swollen PEG chains, it is impossible for the protein molecules to penetrate onto the 
surface layer, reach the surface, and then prevent a cell adhesion response to the 
PEG-variant biomaterials with an adsorbed protein layer [39]. Surface-attached PEG 
chains can assume a wide range of conformations after swelling in water, and they 
required a certain volume. As the protein approaches the surface, it compresses the 
PEG chain, which leads to an entropy loss of the polymer chains (reduction of the 
degree of freedom) and accordingly to a decrease in the Gibbs free energy of the 
system [40]. This makes the diffusion of the protein into the layer energetically 
unfavorable. In particular, cell-repellent surfaces are only valid for very long PEG 
chains in the so-called brush regime, based on a high grafting density. 
2.1.3 Chitosan as an encapsulation agent 
Chitosan is a poly-cationic biopolymer as shown in Figure 2.3 and it is generally 
obtained by alkaline deacetylation of chitin, which is the main component of the 
exoskeleton of crustaceans, such as shrimps [41]. It may also be chemically modiﬁed 
to expand its properties and it has several advantages such as low cost and high 
commercial availability [42-44]. Since chitosan  consists  of molecules with multiple  
positive  charges,  this  polysaccharide can interact with molecules that have negative 
charges, such as glycosaminoglycans present  in  the  extracellular matrix  [44]. 
Moreover, it has another important feature, which is about higher antimicrobial 
activity of chitosan. These features make chitin and chitosan ascendant in drug 
delivery applications. 
CH has structural characteristics similar to glycosaminoglycans.  It has interesting 
biopharmaceutical characteristics such as pH sensitivity, biocompatibility, 
biodegradability, muco-adhesivity, low toxicity and low immunogenicity. Due to 
these favorable properties, the interest in chitosan and its derivatives as tumor-
targeted drug-delivery carriers has been increased in recent years [42]. CH allows 
9 
specific chemical modifications to form a wide range of derivatives since it has 
primary amine groups in the C-2 position and the hydroxyl groups in the C-6 
position of its monomeric units. Chemically modified chitosan derivatives have great 
utility in the formulation of tumor-targeted drug-delivery carriers. 
 
Figure 2.3 : Chitosan chain structure [42]. 
CH is considered to be one of the most widely used biopolymers for nanoparticle 
(NP) preparation because of its unique structural features [45]. It promotes cross-
linkage with various cross-linking agents, such as glutaraldehyde, sodium 
tripolyphosphate (TPP), geneipin, etc., to provide an efficient network to entrap the 
drug molecules into the NPs. Since these NPs exhibit relatively long blood 
circulation times and low uptake by the reticuloendothelial system due to their 
smaller size, they can target the tumor sites through the disorganized and defective 
vascular architecture in tumor tissue, known as the enhanced permeability and 
retention effect. This is often referred to as passive targeting. One major limitation 
with passive tumor targeting alone is its inability to achieve a sufficiently high level 
of drug concentration at the tumor site, resulting in lower therapeutic efficacy and 
eliciting adverse systemic effects. To further improve delivery efficiency and cancer 
specificity, a strong emphasis has been placed on developing chitosan-based NPs 
with active tumor-targeting ability. Active targeting can be achieved by 
functionalizing chitosan and its derivatives with tumor-targeting ligands such as folic 
acid, antibodies, peptides, hyaluronic acid, biotin and avidin, which can recognize 
and bind to specific receptors that are unique to cancer cells.  
CH is extensively studied in brain scaffold preparations and spinal cord implantable 
systems [46]. Moreover, it has displayed multiple bioactivities in various 
investigations carried out in the last decade. It is also widely employed in 
nanoparticle preparation for transportation of loaded drugs to targeted organs in case 
of cancer, diabetes, lung diseases and CNS disorders. CH and its degradation 
products, at the molecular level, exhibits anti-Alzheimer mechanisms majorly by 
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prevention of phosphorylation of c-Jun N-terminal kinase caused by αβ-amyloid, 
inhibition of pro-inflammatory cytokines and blockage of nitric oxide synthase [47]. 
Moreover, biodegradability, biocompatibility, flexibility in surface modification and 
ease of multiple preparation methods are added advantages of chitosan, which makes 
it an attractive nano-shells forming material to achieve successful delivery of drugs 
and nucleic acids to brain interstices.  
Various studies showed that the enzymatic grafting of some phenols onto CH 
backbone such as chlorogenic acid or hexyloxyphenols using tyrosinase enzyme as 
catalyst was effective to obtain water-soluble CH derivatives at physiological 
pH [48]. These CH derivatives can be promoted to use in the pharmaceutical field for 
the production of drugs. The same enzyme was also used to catalyze the enzymatic 
covalent grafting of a de novo designed coil peptide onto chitosan to specifically 
capture proteins tagged with the partner coil peptide such as the epidermal growth 
factor (EGF). This enzymatic approach was considered as a method to obtain easily a 
pure and safe product for biomedical applications such as gene delivery and 
regenerative medicine. Moreover, the M. thermophila laccase was used to produce 
CH derivatives by the grafting of oxidation products of ferulic acid and ethyl ferulate 
onto CH particles in phosphate buffer at pH 7.5. This enzymatic process improved 
the HUVEC cell adhesion on chitosan derivative films compared to CH film, 
promising to use in tissue engineering [49] Microbial transglutaminase (MTGase) 
was also used as enzymatic catalyst to bind collagen peptide with chitosan or with 
carboxymethylated CH. The enzymatic grafting of collagen onto CH contributed to 
enhance antioxidant properties and promote L929 fibroblasts growth. Consequently, 
these CH derivatives could be potential wound dressings for clinical applications and 
showed the potentiality to repair skin in cosmetic, biomedical and pharmaceutical 
fields. 
CH is also a treatment agent for humans with phenolic compounds on Fe toxic 
effects. In fact, under certain physiological conditions, increased iron absorption 
from the diet or due to genetic disorders like hemochromatosis, iron overload or the 
presence of “free” iron occurs [50]. Free iron causes toxic oxygen agents in the body 
via fenton chemistry. Another study discussed the use of Trametes hirsute laccase to 
catalyze the grafting of phenolic compounds onto CH in sodium citrate buffer at pH 
4.5. The microspheres prepared by those functionalized CH derivatives presented 
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high iron-chelating abilities. These microspheres could be extensively investigated 
for drug delivery vehicles for controlled release and targeting studies of almost all 
class of bioactive molecules in medicine [50]. 
Peng et al. have prepared chitosan/αβ-glycerophosphate thermo-sensitive hydrogels 
for the sustained delivery of venlafaxine hydrochloride and studied the optimization 
of the formulation [51, 52]. Release mechanism is investigated by applying various 
mathematical models to the in vitro release profiles. Overall, drug release from the 
hydrogel shows best fit in first-order model and drug release mechanism is diffusion-
controlled release. The results present that higher strength and glycerophosphate 
concentration result in higher initial release and rate constant, which support the 
hypothesis that the kinetic gelation mechanism of this system is nucleation and 
growth [53]. Furthermore, biodegradable poly(3-hydroxybutyrate-co-3-
hydroxyhexanoate) nanoparticles containing insulin phospholipid complex are 
loaded in chitosan/β-glycerophosphate hydrogels for long-term sustained and 
controlled delivery of insulin. In the in vitro release studies, only 19.11% of total 
insulin is released from the nanoparticle-loaded hydrogel within 31 days. Most 
importantly, the hypoglycemic effect of nanoparticle-loaded hydrogel following 
subcutaneous injection in diabetic rats lasts for >5 days, much longer than the effect 
caused by free insulin-loaded chitosan/β-glycerophosphate or other long-acting 
insulin formulations. 
At present, there are several reports available regarding the production and use of 
chitosan nanoparticles as a delivery matrix for the release of pesticides in agriculture 
[54]. As an example, Paula et al. prepared and characterized microspheres composed 
of chitosan and cashew tree gum, which were used as carriers of the essential oil 
of Lippia sidoides, which possesses insecticidal properties [55]. The findings 
indicated the suitability of chitosan for use as matrices to carry bio insecticides 
designed to control the proliferation of insect larvae. Similarly, microcapsules of 
alginate and chitosan were prepared, characterized, and evaluated as a carrier system 
for imidacloprid. The particles obtained were stable and imidacloprid was 
encapsulated with an efficiency of around 82%. In release assays, it was shown that 
the release time of the encapsulated insecticide was up to eight times longer, 
compared to the free insecticide, and that alterations in the concentrations of alginate 
and chitosan affected the release profile. 
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2.1.4 Casein as an encapsulation agent 
Caseins in Figure 2.4 are members of a paralogous group of unfolded 
phosphoproteins, some of which share the ability to sequester amorphous calcium 
phosphate through phosphate centers [56].  
 
Figure 2.4 : Casein from bovine milk chain structure [57]. 
From a product technological and dairy industry point of view the caseins are by far 
the most important and valuable component of milk. The main dairy products as 
liquid milk, cheese and yoghurt derive their textural, sensory and nutritional 
properties from the caseins. Replacing caseins by plant proteins leads to products 
with different textural and sensorial quality [58]. The protein fraction of the CS 
micelles, which represents ~ 93% of its dry mass, is composed of four individual 
gene product components, denoted αs1-, αs2-, β- and κ-casein, which differ in primary 
structure and type and degree of post-translational modification. The remainder of 
the micellar solids consists of inorganic material, collectively referred to as colloidal 
calcium phosphate or micellar calcium phosphate. 
Horne indicated that treating the CSs as block copolymers is an approach that grew 
out of studies of their behavior on adsorption to hydrophobic interfaces [59]. As 
regards the self-association of these proteins, it is speculated that the hydrophobic 
regions interact intermolecularly in solution, rather than compact themselves into a 
folded form. This further implies that they have a certain rigidity that inhibits such 
folding. Such intermolecular hydrophobic interaction leads naturally to the detergent-
like micellar structure observed for β-casein in many studies, with a central 
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hydrophobic core and the hydrophilic peptides forming a hedgehog-like external 
coating.  
For structure and chemical properties CS micelles, Horne also described that from 
the biofunctional viewpoint, the CS micelle is the ultimate level of self-association 
that involves all of the CSs [58]. CS micelles differ from the polymers of the 
individual caseins in one crucial aspect; they contain inorganic calcium phosphate as 
small microcrystalline inclusions, termed nanoclusters.  Because the casein molecule 
has to be readily available to exert such control, this is offered by the proponents of 
the rheomorphic hypothesis as a reason for its open, flexible structure. The 
interaction would, therefore, conform to the inducible binding pathway where 
folding follows binding to the appropriate ligand. 
The widespread or universal distribution of micelles in milk, suggests that they have 
some physiological or nutritional significance over the nutritional value of the 
proteins per se. Two benefits are apparent [60]: 
1. Calcium and phosphate are required for the development of teeth and bone 
and growth rate is positively correlated with the concentrations of Ca and Pi. 
However, calcium phosphate has low solubility at the pH of milk with which 
it is supersaturated; therefore, calcium phosphate would be expected to 
precipitate in the mammary gland, with the formation of etopic stones that 
would block the ducts of the gland, resulting in the death of the organ and 
perhaps of the animal. By forming micelles, casein maintains the excess 
calcium phosphate in a colloidally stable state. Thus, the casein micelles may 
be regarded as a device by which to enable the secretion of milk with a high 
concentration of calcium phosphate in a “soluble” form. 
2. Presumably, the micelles are designed to be coagulated in the stomach of the 
neonate by chymosin, a proteinase designed for this function. Coagulation 
delays the entry of milk constituents into the small intestine, thereby 
improving digestibility. Furthermore, the coagulum acts as a buffer to 
facilitate nursing at intervals that may be very long (24 h) for some species, 
e.g., the hare. 
Strube et al. showed that CSs are also usable for biofilm applications because of   a 
great potential of CS in many applications including biocompatibility, multi-
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functional surfaces, anti-fouling, and biodegradability [61]. In all previous coating 
applications though, casein is simply used as a binder agent. The presented approach 
brings a completely new aspect to the use of casein in this area, as it utilizes the 
complex structure of the micelles and their ability to change its solubility. More 
precisely, it mimics the natural process of the enzymatic casein cleavage, in order to 
form biological coatings with high level of control. The crucial point is the cleavage 
of the casein micelles in direct proximity to the support surface. This prevents 
uncontrolled agglomeration and precipitation. Instead of that, the cleaved micelles 
deposit on the support surface due to hydrophobic interactions.  
Bovine CS is also used to obtain antimicrobial peptide (AMP) which has received 
increasing interest due to the emergence of bacterial resistance and the potential 
toxicity of chemical food preservatives [62]. There is increasing evidence that AMPs 
act through different mechanisms, among which the membrane action mode. 
Although the specific membrane action target of AMPs is not fully understood, it is 
generally believed that the membrane binding process is the initial step when AMPs 
exert bactericidal activity. Zhang et al. demonstrated in their study that the affinity 
interaction between AMPs and the bacterial cell membrane plays a vital role in the 
antibacterial action. 
2.1.3 Sodium alginate as an encapsulation agent 
Alginates are anionic biopolymers extracted from 100% organic sources like brown 
seaweeds. Sodium salt of alginate is also extremely versatile and adaptable 
biomaterial, with great potential for use in biomedical applications such as drug 
encapsulation materials. Their extracellular matrix-like features as seen in Figure 2.5 
have been key factors for their choice as biopolimers for cell delivery at tissue 
regeneration and for drug delivery at encapsulation systems. A variety of strategies to 
decorate them with other biofunctional components to modulate their biophysical 
properties has been developed recently, which further allow their tailoring to the 
desired application [63].  
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Figure 2.5 : Alginate chain structure [63]. 
SA is of the most popular natural polymers which has been investigated for wound 
dressing application incorporating with polyvinyl alcohol (PVA) polymer as either 
main or additional component to the dressing structure due to its high water swelling 
ability which impacts the local wound environment beyond moisture management 
[64]. Kim et al. have used PVA/alginate hydrogel containing nitrofurazone for 
wound dressing purposes, where they have used the freeze–thawing method to 
crosslink PVA/SA blended polymer [65]. They have reported that the increase of SA 
concentrations in PVA hydrogel films, increased the swelling ability, elasticity, and 
thermal stability of PVA/SA hydrogel films while, significant decreases in gel 
fraction%, and mechanical properties of PVA/SA hydrogel film were found with 
increased SA contents. They have also conducted the bio-evaluation of PVA/SA 
hydrogel films, and they revealed that increased SA contents resulted in the protein 
adsorption in vitro increases, indicating the reduced blood compatibility. 
Furthermore, in vivo experiments showed wound size reduction in rats, indicating a 
better wound healing ability proportionate to the amount of SA incorporated into 
PVA hydrogel films. 
Levic et al. have made an efficient encapsulation matrix for d-limonene 
encapsulation using crosslinking of PVA/SA by the freeze–thawing method, 
followed by a calcium ionic interaction between alginate and CaCl2 solution but 
these hydrogels do not apply for wound dressing but for food processing application 
[66]. This study showed that increasing SA concentration decreased the gelation (%), 
maximum strength and break elongation, but it resulted in an increment in the 
swelling ability, elasticity and thermal stability of the hydrogel film. However, SA 
content had an insignificant effect on the release profile of clindamycin from the 
PVA/SA film, whereas PVA/SA-clindamycin improved the healing rate of artificial 
wound in rats. 
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Tarun and Gobi presented a new concept for the synthesis of the nanocomposite web 
of calcium alginate and PVA with varying proportions using an electrospinning 
technique for wound healing application [67]. They have demonstrated that the 
blended nanofiber composite web which has the maximum calcium alginate content, 
showed the maximum water vapor transmission rate indicating the PVA/SA 
nanofiber web helps in maintaining the local moist environment for accelerating 
wound healing. Furthermore, in vivo experiments on rats exhibited apparently new 
epithelium formation without any harmful reactions, when the wound is covered with 
the PVA/SA nanofiber. This study has classified wound dressing material formation 
which is based on PVA/SA into three categories as follows: (a) dressings containing 
a significant proportion of SA to improve the gelling properties of the dressing in 
use, (b) dressings obtained by the freeze-dried PVA/SA film or γ-ray irradiation 
techniques, and (c) dressings formed depending on the bond between an exuding 
wound and an ion-exchange reaction, occurring due to the calcium ions in the 
dressing and sodium ions in the serum or wound fluid [64]. 
Stulzer et al. showed encapsulation efficiency of SA in microparticle system to 
provide controlled drug release [68]. In this study, SA and CH is used microparticle 
agent for encapsulation of a high molecular weight molecule rifampicin. The 
microparticles are prepared by gelatinizing method during a 30-min period in contact 
with the precipitating solution and were then filtered, washed with distilled water and 
dried at room temperature. The results obtained showed that the SA/CH 
microparticles represent an efficient system for the controlled-release of rifampicin. 
At acidic pH, the release of 20% of the drug occurred in 2 h, and at pH 6.8 a rapid 
increase in the release rate was observed up to 100%. 
Kim et al. are described with detailed models using of SA hydrogels for bone tissue 
engineering applications in their paper [69]. Alginate hydrogels or scaffolds can be 
prepared by diverse range of cross-linking agents that are majorly calcium-based 
substances. When sodium alginate is placed into the calcium-based ion, the calcium 
ion replaces the sodium ion in the polymer; each calcium ion is cross-linked with two 
moieties of polymer strands. Alginate scaffolds are being actively explored for their 
ability to facilitate the regeneration of other tissues and organs, including skeletal 
bone, skin, nerve, liver and pancreas. Different kinds of methods including 
lyophilization, electrospinning and cross linking, have been extensively studied to 
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prepare the alginate scaffolds. Traditional method to produce the alginate biopolymer 
scaffold is freeze dry-lyophilization method.   
Bioactive glasses comprise of glass-ceramic biomaterials and are extensively studied 
materials for implantation in the human body to repair/replace the defective or 
diseased bone. Mishra et al. prepared the scaffold viz. bioactive glass-polyvinyl 
alcohol-alginate biocomposite materials by surfactant foaming, having low-density 
0.92 g/cm
3
 along with pore size 200–500 μm [70]. Synthesized biocomposite shows 
excellent biocompatibility with fibroblast cells with compressive strength of 
1.64 MPa and elastic modulus of 18 MPa. In another study, Luo et al. reported 
mesoporous bioactive glass and concentrated alginate paste scaffolds by 3D plotting 
techniques [71]. Addition of mesoporous silica material increased the mechanical 
strength, apatite mineralization and cytocompatibility properties of the composite 
scaffold. In addition, dexamethasone was incorporated for the delivery purpose for 
better bone regeneration. Compressive strength of 50% mesoporous bioactive 
glass/alginate scaffolds was reported to be significantly higher than pure alginate 
scaffolds. Enhanced mineralization and protein adsorption was observed on addition 
of bioactive glass in alginate. Furthermore, human periodontal ligament fibroblast 
and osteosarcoma cells were viable, adhered and proliferated well on the alginate-
nanobioactive glass composite scaffolds in comparison to the control alginate 
scaffolds. 
Different kinds of biocomposite materials have been established to improve the 
bioactive properties of the scaffold via chemical modification, including the 
immobilization of functional cell-adhesive ligands and bioactive molecules such as 
enzymes, drugs and cytokines. SA is widely utilized in medical area for tissue 
engineering and regeneration due to its biocompatibility, non-thrombogenic nature, 
easily handled from nature, mild and physical gelation process, and the resemblance 
of its hydrogel matrix texture and stiffness to that of the extracellular matrix. The use 
of bioactive molecules (growth factors, cytokines, and stem cell mobilizing factors) 
has always been of interest in the field of therapeutic myocardial regeneration. The 
effects exerted by these molecules are relevant to almost every target in regeneration 
strategies, such as cell survival and proliferation, vascularization apoptosis 
inhibition, progenitor/stem cell migration, and directed stem/progenitor cell 
differentiation. In addition, systemic administration requires high doses of the protein 
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in order to achieve optimal concentration at the specific target site, due extremely 
low protein stability in the circulation which leads to fast elimination of the protein. 
Moreover, most of these molecules have pleiotropic functions, emphasizing the need 
for careful, local and time-adjusted interventions. Thus, biomaterials could be 
engineered to produce a sustained delivery system for bioactive molecule 
combinations. Due to the Cohen and Ruvinov, in such a system, the biomaterial will 
provide structural temporary matrix support and direct the formation of functional 
tissue in situ [72]. Simultaneously, it will serve as a temporary depot for sustained 
delivery and presentation of bioactive molecules with spatial and controlled 
distribution of the desired agent to induce multiple reparative/regenerative processes. 
In general, due to low protein adsorption and its highly porous and hydrophilic 
nature, the pristine unmodified alginate matrix yields fast and unpredictable protein 
release kinetics. Thus, several modification designs and engineering schemes were 
applied for the use of alginate in protein delivery. 
2.2 L-Ascorbic acid as an active ingredient 
L-ascorbic acid is a naturally occurring organic compound with antioxidant 
properties.  It was originally called L-hexuronic acid, but when it was found to have 
vitamin C activity in animals. It  is  a  lactone  which  contains  six  carbons  and  an  
essential  vitamin  for  humans because  of  antioxidant  properties  and  cofactor  
agent  in  enzymes  [73].  Chemical structure of L-ascorbic acid was shown in Figure 
2.6. 
 
Figure 2.6 : Structure of L-ascorbic acid [73]. 
L-ascorbic  acid  appears  in  so  many  biologic  applications  in  human  body,  for 
example in bone, teeth, cartilage, and skin as collagen agent; in enzymes as cofactor 
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agent [74]. However, it is a very sensitive material and pH, temperature, oxygen, 
metal ions, UV, and X-ray radiation can easily damage its structure. 
L-ascorbic acid is a required nutrient for a variety of biological functions. Humans 
and other primates have lost the ability to synthesize ascorbic acid due to a defect 
in L-gulono-1,4-lactone oxidase, an enzyme that catalyzes the conversion of L-
gulonolactone into ascorbic acid [75]. Humans, primates, and a few other animals 
(e.g., guinea pigs) depend on the diet as a source of L-ascorbic acid to prevent the L-
ascorbic acid deficiency disease, scurvy, and to maintain general health. Another 
healthy effect of L-ascorbic acid can be attributed to its biological functions as a 
cofactor for a number of enzymes, most notably hydroxylases involved in collagen 
synthesis, and as a water-soluble antioxidant.  
 
Figure 2.7 : L-ascorbic acid acts as a cofactor for prolyl 4-hydroxylase [76]. 
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It can also function as a source of the signaling molecule, hydrogen peroxide, and as 
a Michael donor to form covalent adducts with endogenous electrophiles in 
plants. One of them the functions and the underlying mechanisms is illustrated in 
Figure 2.7 [75]. 
Since the discovery of L-ascorbic acid, the number of its known biological functions 
is continually expanding [77]. Both the names ascorbic acid and vitamin C reflect its 
antiscorbutic properties due to its role in the synthesis of collagen in connective 
tissues. L-ascorbic acid acts as an electron-donor keeping iron in the ferrous state 
thereby maintaining the full activity of collagen hydroxylases; parallel reactions with 
a variety of dioxygenases affect the expression of a wide array of genes as well as via 
the epigenetic landscape of cells and tissues. In fact, all known physiological and 
biochemical functions of L-ascorbic acid are due to its action as an electron donor.  
The repeatedly ageing effects of oxidants has led to negative impression on prolong 
lifespan, so antioxidant dietary is suggested recently. L-ascorbic acid is an essential 
antioxidant in human diets and is widely used for supplementation. It is one of the 
most important water soluble and easily handled antioxidants; ever since the free 
radical theory of ageing was discovered forward 50 years ago [78]. Therefore, 
humans and animals depend on their diet as a source of L-ascorbic acid to prevent 
scurvy, produce essential enzymes and maintain general health. It is included 
primarily through the consumption of herbals such as fruit, vegetables; some 
artificial drinks  and supplements. It has been shown to be important for the synthesis 
of collagen, carnitine, and catecholamines; the impaired production of which leads to 
the symptoms associated with scurvy. The health promoting effects of L-ascorbic 
acid can be attributed to its biological functions as a co-factor for a number of 
enzymes, such as hydroxylases involved in synthesis of collagen in the body, and as 
a water-soluble antioxidant for anti-ageing. It donates two electrons from a double 
bond between the second and third carbons of the 6-carbon molecule as seen in 
Figure 2.7. It is hypothesized that by donating its electrons, L-ascorbic acid prevents 
proteins and other cellular compounds from being oxidized, so it helps anti-ageing 
[79].  
There has been considerable interest regarding the association of L-ascorbic acid 
with the common cold. Banerjee et al. studied effect of L-ascorbic acid on prevention 
of influenza and they indicates in their article that mega doses of L-ascorbic acid 
21 
(3 g/d) have been shown to prevent cold and flu symptoms in students 18–30 y of 
age; on the other hand, lower doses of L-ascorbic acid have not been shown to 
prevent cold symptoms in a number of trials [80]. They indicates that doses of L-
ascorbic acid in excess of 1 g/d taken shortly after onset of a cold symptom did not 
decrease the duration or severity of cold symptoms in healthy adult volunteers when 
compared with a L-ascorbic acid dose lower than the minimum recommended daily 
intake. In a controlled trial of 226 patients with influenza A, 114 patients received L-
ascorbic acid 300 mg/d, and 112 patients served as controls; outcomes measured 
were development of pneumonia and duration of hospital stay. Pneumonia was 
reported in two subjects in the treatment group and 10 in the control group, and 
hospital stays for influenza or related complications averaged 9 d in the L-ascorbic 
acid group and 12 d in the control group.  
Another interest of usage area for L-ascorbic acid is anti-tumor treatments because of 
its antioxidant effects [81]. By disarming biologically damaging molecular fragments 
known as free radicals, L-ascorbic acid can fight devastation effect of aging and 
many chronic diseases. Free radicals also offer benefits, however, such as ridding the 
body of germs and damaged cells. By curbing these activities, a new animal study 
finds, antioxidants can aid cancer growth. Because of these reasons, it has become 
the ost wanted antioxidant of the nutritional world [82]. Free radicals of reactive 
oxygen and nitrogen species that have potential to damage nucleic acids and promote 
carcinogenesis and they are generated in response to high concentration of L-
ascorbic acid can catalyze lipid peroxidation and are cytotoxic to cancer cells. Within 
the body, antioxidant levels act as a signal, controlling cell division. In healthy cells 
and benign tumors, oxidants tend to increase cell proliferation, whereas antioxidants 
inhibit it. By contrast, the malignant tumor environment can be so strongly oxidizing 
that it is damaging and triggers cell death by apoptosis. In this case, antioxidants may 
help tumor cells proliferate and survive, by protecting the cells against oxidation and 
stimulating the malignancy to grow. L-ascorbic acid presents a double-faced 
character in that it exhibits a pro-oxidant activity arising from its routine antioxidant 
property. Apart from reducing oxidizing sources like H2O2, L-ascorbic acid also 
reduces metal ions like Fe
3+
 and Cu
3+
, the process during which free radicals are 
generated. This reaction in which L-ascorbic acid generates highly reactive free 
radicals in presence of transition metal ions is called Fenton reaction [81].  
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2Fe
3+
 + L-ascorbic acid → 2Fe2+ + DHA                                                 (2.1) 
2Fe
2+
 + 2H2O2 → 2Fe
3+
 + 2OH
−
 + 2OH*                 (2.2) 
These hydroxyl radicals are reported to interact with DNA inducing its damage by 
causing breaks in phosphodiester backbone and modification of DNA bases. This 
property of pro-oxidant activity inducing cytotoxicity has been employed in many 
studies in the prevention and treatment of cancers and is proposed to be dose-
dependent. 
2.3 Drug Encapsulation Techniques 
New drug delivery technologies are revolutionizing the drug discovery; development 
and creating R&D focused pharmaceutical industries to increase the momentum of 
global advancements. In this regard, novel drug delivery systems (NDDS) have many 
beneﬁts, which includes improved therapy by  increasing  the efficiency and duration 
of  drug  activity,  increased  patient  compliance  through  decreased  dosing  
frequency and convenient routes of administration and improved site speciﬁc 
delivery to reduce the  unwanted  adverse  effects.  
The basic principles for development of drug delivery systems are easily integration 
of active ingredient into drug, achieving of higher drug release ratios, and non-toxic 
effects of drug capsule to cells after its biodegradation. The last ten years, production 
of more effective, biocompatible, and biodegradable drug systems have been 
increasingly interest for pharmaceutical industry [18,23].  Nowadays, polyester based 
biopolymers are used for drug delivery and encapsulation systems and some 
examples of these polymers are PCL, PEG, PLA, PGA, polyacrylic acid (PAA), 
poly(methyl methacrylate) (PMMA), chitosan, chitin, and starch [83]. 
It is another important issue for drug delivery systems is that stability at outside and 
sufficient degradation of drugs inside of human body. To overcome this problem, 
polymeric based drug delivery systems could be an enormous alternative because 
biodegradation rate is easily adjustable by blends of polymers [84]. In this way, 
stability, effective biodegradation rate, and higher drug release contents for a drug 
could be achieved simultaneously.  
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Stability of a drug is depends on protection capacity of active ingredient, thus if a 
polymer is used for an encapsulation system, it interact temporarily stable between 
active ingredient to deliver system on targeted cells before releasing.   
At these view of points, preparing of a drug, which is easily biodegradable, 
biocompatible inside the body and stable outside the body, is the main problem and 
most important goal for pharmaceutical industry. 
Encapsulation  may  be  defined  as  a  process  to  entrap  one  substance  within  
another substance,  thereby  producing  particles with  diameters of  a  few  nm  to  a  
few mm. The substance  that  is  encapsulated may  be  called  the  core material,  the  
active agent, fill, internal phase, or payload phase. The substance that is 
encapsulating might also be called the coating, membrane, shell, carrier material, 
wall material, external phase, or matrix. Two main types of encapsulates might be 
distinguished, i.e., the reservoir type and the matrix type [12].  
The most widely used encapsulation techniques and some related applications are 
summarized in Table 2.1.  
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Table 2.1 : Main conventional techniques used for the encapsulation of bioactives 
and food ingredients [85]. 
Technique Concept Examples of applications 
Spray drying 
Drying of the encapsulated 
material dispersed in the shell 
material.  
Encapsulation by starch, 
polysaccharides, maltodextrins 
and/or proteins. This technique 
produces particles between 10 
and 100 μm. 
Encapsulation of flavor 
compounds, polyphenols 
and vitamins 
Spray cooling/chilling 
Incorporation of the core 
material in the warm and 
liquefied shell material (often-
vegetable oils). Relatively low-
cost encapsulation technique. 
Through product atomization, 
and consequently cooling, 
micro-capsules are formed. 
Encapsulation of flavor 
compounds, minerals, 
vitamins and probiotics 
Freeze drying 
Co-lyophilization of the core 
and the shell materials after a 
homogenization process. 
Normally this technique 
produces non-uniform 
particles. 
Encapsulation of flavor 
compounds, fatty acids 
and probiotics 
Extrusion 
Formation of core material 
droplets that became 
microparticles after immersion 
in a hardening bath with the 
shell material. Normally the 
shell material is a glassy 
carbohydrate matrix. The core 
material may be released in a 
high temperature medium. The 
encapsulation efficiency is 
small, moreover the produced 
particles show high stability 
and an extended shelf-life. 
Encapsulation of flavor 
compounds, vitamins and 
food ingredients (lactic 
acid) 
Spinning disk 
Passage through a spinning 
disk of a suspension of the core 
material in the shell material. 
During processing, the shell 
material forms a thin film 
around the core material 
particles. Production of 
particles from 20 μm to few 
millimeters of diameter. 
Encapsulation of cells 
(yeast) 
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Table 2.1 (continued) :  Main conventional techniques used for the encapsulation of 
bioactives and food ingredients [85]. 
Technique Concept Examples of applications 
Supercritical fluid 
extraction 
This technique is similar to 
spray drying, except that the 
shell material and the core 
material are 
solubilized/dispersed in a 
supercritical fluid. 
Encapsulation of heat-
sensible cores as vitamins 
and polyphenols 
Fluidized bed 
Solid particle encapsulation 
(100 μm to few mm). The shell 
material is atomized onto core 
material fluidized by an 
upward stream of air. 
Encapsulation of 
acidulates, vitamins and 
cells 
Co-crystallization 
Spontaneous crystallization of 
a supersaturated solution of 
sucrose simultaneously with 
the addition of the core 
material, forming a crystalline 
irregular network, allowing the 
encapsulation into the pores of 
the network. 
Encapsulation of acids, 
flavor compounds, 
antioxidants and minerals 
Co-acervation 
Phase separation of one or 
many polyelectrolytes from a 
solution and deposition of the 
colloidal particles around the 
active ingredient suspended or 
emulsified in the same reaction 
media. When hydrocolloids are 
used, they can be cross-linked 
using appropriate chemical or 
enzymatic agent. 
Encapsulation of fatty 
acids and flavonoids 
Liposomes 
Spherical particles consisting 
of a membranous system 
formed by one or more 
concentric bi-layers of lipids 
(often phospholipids). They 
can be used in the entrapment, 
delivery and released of water-
soluble, lipid-soluble and 
amphiphilic materials. 
Encapsulation of vitamins, 
enzymes and peptides 
Inclusion 
Supra-molecular association 
through non-covalent 
interactions of a ligand 
(“encapsulated” compound) 
into a cavity formed by a 
“shell” material (e.g., 
cyclodextrins). 
Encapsulation of vitamins, 
flavor compounds and 
essential oils 
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Liposomes, micelles and microparticles (as seen in Figure 2. 8 (a), (b), (c), 
respectively) are the most attractive ways to produce effective drug delivery systems.   
 
(a) 
 
(b) 
 
(c) 
Figure 2.8 : Schematic representation of the structures of (a) liposomes, (b) 
micelles, (c) microparticles [86]. 
It is always a fact that performance of a drug delivery system is about encapsulation 
and release efficiency. One of the basic requirements for the controlled and balanced 
release  of  the  medicament  in  the  body  is  its  ideal  spherical  shape  of  
polymeric particles  and narrow distribution of  their  sizes. The  size  and  shape of  
the particles play  key  role  in  their  adhesion  and  interaction  with  the  cell.  The 
most important problem  for  polymer  based  drug  delivery  systems  is  lower  drug  
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loading  and  drug release efficiency [87]. On the other hand, drug loaded 
microspheres have to be lower particle size (about 10 μm) and well distributed.  
Emulsion solvent evaporation technique is widely used in the field of particulate 
carriers’ development. It consists of the formation of a simple or a double emulsion 
and the subsequent evaporation of the organic solvent which leads to the 
precipitation of the polymer and the obtaining of the particles. More precisely, first, 
the polymer is dissolved in a volatile and non-miscible organic solvent such as 
chloroform, ethyl acetate, toluene, tetrahydrofuran or dichloromethane. This organic 
phase is then dispersed by high-speed homogenization or by sonication in an aqueous 
phase that contains a surfactant. Once an oil-in-water (o/w) emulsion is obtained, the 
evaporation of the organic solvent allows its diffusion to the outer phase leading to 
the formation of the particles. This method of simple emulsion solvent evaporation is 
generally used for the encapsulation of hydrophobic drugs. Besides,  drug  delivery  
systems  which  are  obtained  by  oil/water  emulsion  based mixture, has man 
disadvantages. The main reason of this problem is using of toxic organic  solvents  in  
these  systems, so it could  have  a  potential  harmful  effect  on human body. 
Furthermore, organic solvents-active ingredients interactions may have adverse side 
effect for drugs [88]. Thus, using water as a solvent for drug preparation has become 
more important since last decade. Contribution of water on zero  toxicity  and  higher  
biocompatibility  of  drugs  for  human  cells makes  it more important for drug 
delivery synthesizing systems.       
Novel technologies are required for delivery of new drug molecules in order to 
reduce their side effects, optimize their efficacy, and enhance patient compliance. 
Due to the Farokhi et al., recently, the use of nanotechnology has led to the 
development of many novel carriers capable of controlled release and targeted 
delivery of a wide range of small molecules, proteins, peptides, and genes [89]. 
These devices can have many different structures, including quantum dots, 
dendrimers, fullerenes, ferritin, and nanoparticles. Among them, nanoparticles based 
on biodegradable and biocompatible polymers have potential applications in cancer 
therapy and as sustained drug delivery vehicles. These carriers can also be designed 
as low toxicity systems with suitable physical and chemical structures and specific 
targeting properties. 
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Another important study about nanoparticles on drug delivery systems by Hua et al. 
are described that improved oral drug delivery design has drastically improved the 
colonic bioavailability of drugs, that is, these formulations are effective at reaching 
and releasing drug specifically in the colon [90]. However, in order for a drug to 
have therapeutic efficacy it must be localized to the site of action within the colon. 
Conventional oral formulations can be adversely affected during active inflammatory 
bowel disease (IBD) or following intestinal resection, and have limited efficacy and 
specificity for diseased colon tissue versus healthy colon tissue. In addition, despite 
coverage of the colonic surface (including diseased tissue), there is no guarantee that 
the drug is effectively taken up into the tissue and cells at the site of inflammation. 
Pharmaceutical strategies utilizing nano-delivery systems as carriers for active 
compounds have shown promising results in addressing the physiological changes in 
IBD, and exploiting these differences to enhance specific delivery of drugs to 
diseased tissue. Therefore the use of nanotechnology in formulation design may 
further improve the efficacy of therapeutics by allowing inflammation-specific 
targeting and uptake within the colon. Furthermore, reducing the size of drug 
delivery carriers to the nanometer scale has been shown to improve colonic residence 
time in inflamed intestinal regions and provide additional benefits for IBD therapy 
Nano-delivery systems have been designed to passively or actively target the site of 
inflammation. These systems have been shown to be more beneficial than 
conventional formulations, because their size leads to more effective targeting, better 
bioavailability at diseased tissues and reduced systemic adverse effects. Hence, nano-
delivery systems have been found to have similar or improved therapeutic efficacy at 
lower drug concentrations in comparison to conventional formulations [91]. 
Although size is an important factor in targeting the colon, additional strategies to 
enhance drug delivery to inflamed intestinal mucosa and achieve maximal retention 
time in tissues are being explored.  
Liposomes are  most commonly studied and used encapsulation systems because of 
fabrication of liposomes form food-grade components using relatively simple 
laboratory-scale methods [92]. On the other hand, liposomes production is really 
hardo to scale indusctrial level. Furthermore, their poor physical stability under the 
environmental conditions is another problem. In additionally, encapsulation 
efficiency of liposomes is generally low for hydrophilic active ingredients, Because 
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of these reasons mentioned above, liposome productions are not effective and 
economic at large scale.    
Microencapsulation has been defined as “the technology of packaging solid, liquid 
and gaseous materials in capsules at micro-scale that release their contents at 
controlled rates over prolonged periods of time” [93]. Microencapsulation technique 
is used in various applications like pharmaceutics, cosmetics and food industries. In 
food applications, several purposes are targeted; firstly, the stabilization of the 
encapsulated product against damage caused by external conditions such as light or 
heat during processing during storage; secondly, flavor release control; thirdly, colur 
and taste protection; finally, reactive species separation [94]. Microencapsulation 
within spherical microparticles possesses many benefits over other encapsulation 
geometries, including a high surface area to volume ratio, a high resistance to 
mechanical stress, a relatively short diffusion path length, and access to a number of 
implantation sites by injection. Moreover, while microencapsulation process, 
chemical structure of the active ingredient and/or food compounds should not be 
changed. With this aim in mind, the challenges that must be met by encapsulation are 
multiple: i) increasing stability of encapsulation, ii) not effecting on sensitivity of 
drug compounds, iii) improving the release ratio of drug compounds. 
Hag et al. and Kowalczuk et al. indicate that the mechanism of microencapsulation 
can occur within unimolecular micelles in three different ways [95, 96]. The guest 
can be encapsulated in the core, in the shell, or at the interface of the core and the 
shell of unimolecular micelles as shown in Figure 2.9 (a), (b), (c). In addition to this, 
it was found that unimolecular micelles, although they represent single-molecule 
micelles per se, do not necessarily transport their cargo in a unimolecular fashion. 
Instead, the microencapsulation can occur in a fourth way, whereby the guest is 
encapsulated within aggregates of several unimolecular micelles (Figure 2.9 (d)). 
The fourth microencapsulation mechanism is therefore not unimolecular but 
supramolecular. 
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Figure 2.9 : Four different microencapsulation mechanisms in core–shell 
architectures [95]. 
Depending upon the mechanism of transport, the size of the micro-carrier could also 
vary, which is an important factor that needs to be considered for the design of a 
successful drug delivery system. For instance, transport through supramolecular self-
assembly results in larger aggregates. In general, the size of the micro-carriers that 
transport through unimolecular mechanisms varies from a few nanometers to tens of 
nanometers depending on the molecular weight of the system. 
The reservoir type has a shell around the active agent. This type is also called 
capsule, single-core, mono-core or core-shell type. Application of pressure can  lead  
to breakage  of  the  reservoir  type  of  encapsulates  and  thus  to  the  release  of  its  
contents. Poly- or  multiple-core  type  of  encapsulates  with  several  reservoir  
chambers  in  one particle also exist. The active agent in the matrix type is much 
more dispersed over the carrier material; it can be in the form of relatively small 
droplets or more homogenously distributed over encapsulation. Active agents in the 
matrix type of encapsulates are in general also present at the surface, in contrast to 
those in the reservoir type [96-100]. 
Inhalation of powder compounds is an attractive concept minimizing the side effects 
by its pulmonary selectivity. Controlled drug delivery systems have become 
increasingly attractive options for inhalation therapies.  A large number of carrier 
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systems have been developed and investigated as potential controlled drug delivery 
formulations to the lung, including drug loaded lipid and polymer based particles. 
However, there are some extraordinary specifications should have for a drug delivery 
material [101]. 
Heng et al., Peltonen et al., and Vehring were also showed encapsulation composite 
or material  should  be  in  amorphous  phase  for  physical  stability  of  drugs  [102-
104]. Because  of  good  biodegradation  behavior  in  human  body  and  
contribution  on homogeneous  distribution  of  active  ingredients  in matrix  of  
amorphous  polymers, they are preferred in pharmaceutical industry. In addition, 
these studies showed that amorphous composites could be easily obtained by spray 
dryer. Another positive impact  of  using  of  spray  dryer  is  that  achieving  lower  
particle  diameter,  well distributed microspheres and as possible as higher surface 
area in only one process.  
In  the  study  of  Bee  et  al. was  demonstrated  that  ester  and  ether  bonds  
contained polymer are more effective for using of encapsulation material such as 
cellulosic and lingo-cellulosic polymer chitosan, chitin etc.  [105]. Moreover, they 
were emphasized that when developing solid-dispersion formulations of poorly 
soluble active ingredients, one must do the following: comparison of the functional 
groups of both polymer and active ingredients; comparison  of  solubility  parameters 
with  polymer and  active  ingredients;  analyzing  the  permeability  of  active  
ingredients  in  the polymer matrix. Consideration of only one parameter is not a 
good approximation to produce  a  stable  drug  because  all  factors  such  as  
solubility,  permeability,  toxicity, productibility,  efficiency,  and  interaction  
between  polymer  and  active  ingredients must be handled at the same time. On the 
other hand, Taylor et al. also showed that polymer hygroscopicity is another 
important parameter for physical stability of drugs [106].  Absorption  of  moisture  
from  air  of  a  drug  means  that  initiation  of  phase separation in the drug, so 
activity and stability of drug decreases dramatically. Thus, using of highly 
hydrophobic polymer should be a must in encapsulation materials. For these  
systems,  water  was  found  to  disrupt  drug-polymer  interactions,  which, coupled  
with  the  ability  of  water  to  increase  molecular  mobility,  led  to  phase 
separation. 
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2.4 Drug Release Mechanism and Kinetics 
Drug release has been an important topic in the field of drug delivery for decades. 
With advancement in material design and engineering, novel materials with 
increasing complexity and more functions have been introduced into the 
development of drug delivery devices and systems [107]. Both naturally derived and 
synthetic macromolecules are extensively used in controlled drug release to 
maximize bio-efficacy. Control release is a useful tool to maintain constant drug 
levels in the human body. 
Drug release from polymeric carriers involves several mechanisms [107]. Depending 
on the polymeric structure, the drug might be released by diffusion through the 
polymeric matrix or through pores present in the carrier. Erosion of the carrier 
surface or bulk erosion can also lead to drug release. The high surface area to volume 
ratio of polymeric carriers contributes to a rapid drug release from the matrix which 
is called a “burst”. This phenomenon can be reduced by drug complexation with 
various agents before encapsulation as well as by adding lipid aid excipients to the 
formulation [108]. Complexing agents or lipid aid excipients interact with the 
encapsulated compound and these interactions increase encapsulation efficiency as 
they decrease the burst.  
Types of controlled drug release systems are listed below: 
1. Dissolution controlled systems 
a) Encapsulation dissolution controlled system. 
b) Matrix dissolution controlled systems. 
2. Diffusion controlled systems 
a) Reservoir controlled systems. 
b) Matrix controlled systems. 
3. Dissolution and diffusion controlled release systems 
4. Water penetration controlled systems 
a) Swelling controlled systems 
b) Osmotically controlled systems. 
5. Chemically controlled release systems 
a) Erodible systems 
b) Drug covalently linked with polymer 
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6. Hydro gels 
7. Ion - exchange resin controlled release systems 
2.4.1 Dissolution controlled release systems 
The dissolution of a drug administered in the solid state is a pre-requisite for efficient 
subsequent transport within the human body. This is because only dissolved drug 
molecules/ions/atoms are able to diffuse, e.g. through living tissue [109]. In this 
system, dissolution is the rate controlling step which is shown in Figure 2.10  
 
Figure 2.10 : Dissolution of a solid drug particle in an aqueous liquid [109]. 
The drug release occurs by dissolution and/or erosion of encapsulation material 
matrix. It is of two types and they are; 
a) Encapsulation dissolution controlled system 
b) Matrix dissolution controlled system 
On the first method, the drug particles are encapsulated by microencapsulation 
technique by coating agents like cellulose, CH, PEG, PLA, polymethacrylates, waxes 
etc. the dissolution rate of capsulation depends upon the solubility and thickness of 
the coating. 
Matrix systems depend on dispersion of active ingredients homogeneously into the 
release medium. Waxes such as beeswax, carnauba wax, hydrogenated castor oil are 
employed as matrix systems release agents and they allow controlled release of 
active ingredients by altering the porosity of rate. 
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2.4.2 Diffusion controlled release systems 
Diffusion is a process of moving molecules from a solution of high concentration to 
low concentration.  There are two basic devices that are driven by diffusion in 
controlled release systems. In these devices, the drug is released either by passing 
through the pores or between polymer chains, and these are the processes that control 
the release rate. Diffusion controlled release devices; 
a) Reservoir  diffusion system  
b) Matrix diffusion system  
Active ingredients are dispersed homogeneously into the matrix diffusion systems 
(monolithic devices), and it is released by diffusion from the polymer into the release 
mediums as shown in Figure 2.11. The release rates of monolithic devices decrease 
as a function of time and distance.  
 
Figure 2.11 : Matrix diffusion systems [110]. 
Reservoir diffusion systems are also called as membrane-controlled 
systemssurrounds the active ingredients and released drugs by diffusion through the 
release mediums (Figure 2.12). 
 
Figure 2.12 : Reservoir diffusion system [110]. 
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2.4.3 Dissolution and diffusion controlled release systems 
In dissolution and diffusion controlled release systems, the drug core is 
coated/capsulated in a partially soluble membrane. Pores in the encapsulation system 
are generated due to dissolution of parts of the membrane which; 
 Drug dissolution performed by entry of aqueous medium into the 
encapsulation system 
 Allowing diffusion of drug out of the encapsulation system. 
An example of obtaining such an encapsulation system is using a mixture of 
biopolymers like PCL, PEG, CH, CS as in our study. 
2.4.4 Water penetration controlled systems 
Water diffusion (penetration) into the system is obtained by controlling on the 
penetration of water into the system. On the other hand, swelling controlled release 
systems are determines as drug is initially dry and when it is placed in the body 
absorb water or other body fluids and swell. Swelling-controlled devices usually 
incorporate drugs in a hydrophilic polymer and/or gels that are stiff or glassy when 
dry, but swells when placed in an aqueous environment (Figure 2.13). A typical oral 
capsule or pill (obtained commercial) is usually a swelling-controlled device.  These 
drugs are easy to handle and produce, but the release rates are often not steady and 
effective.  
 
Figure 2.13 : A typical swelling controlled release system [111]. 
2.4.5 Osmotically controlled release systems 
Osmotically controlled release systems (Figure 2.14) are used to encapsulate 
osmotically active drug or a combination of an osmotically inactive drug with an 
osmotically active salt e.g. NaCl within a semi permeable membrane made from 
biocompatible polymer, e.g. cellulose acetate. Osmotically controlled release systems 
36 
generates osmotic pressure, so active ingredient in the core is pumped out 
continuously with a prolonged period of time. This type of drug system dispenses 
drug solutes continuously at a zero order rate.  
 
Figure 2.14 : Elementary osmotic released system [112]. 
2.4.6 Chemically controlled release systems 
Chemically controlled release systems are different drug release systems mentioned 
above. They change their chemical structure, when exposed to biological fluid. 
Mostly, biodegradable and biocompatible polymers are used for chemically 
controlled release systems by degradation of polymer structure as a result of 
hydrolysis and/or erosion of the polymer chains into biologically safe and 
progressively smaller moieties. It is of two types and they are; 
 Erodible systems 
 Pendent chain system 
In erodible systems, drug release mechanism occurs by erosion of polymer. Erosion 
may be two types as seen in Figure 2.15 and they are; 
a) Bulk erosion process  
b) Surface erosion process 
 
Figure 2.15 : Drug release (a) bulk erosion, (b) surface erosion [113]. 
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Bulk erosion is polymer degradation may occur through bulk hydrolysis of the 
polymer which means entire polymer matrix are degraded by this way. On the other 
hand, surface erosion is polymers like polyorthoesters and polyanhydrides etc. occurs 
degradation only at the surface of the polymer, resulting in a limited drug release 
ratio that is proportional to the surface area of the delivery system. 
Pendent chain systems consist of copolymers, polymeric blends and composites with 
the drug attached to the backbone chains. The drug is released from the entire core 
by hydrolysis or enzymatic degradation of the linkages. Zero order can be obtained 
and the cleavage of the drug is the rate controlling mechanism. Example for  
polymers used in pendent chain systems like chitosan, PEG etc. 
2.4.7 Hydrogels controlled release systems 
Hydrogels are water swollen three-dimensional structures handled by primarily 
hydrophilic polymers. Because of chemical or physical cross-links, they are insoluble 
in water. The physical cross-links include crystallites, entanglements or weak 
associations like hydrogen bonds or Vander Waals forces. These cross-links supply 
strength, physical integrity and network structure. Chemically instable and weak 
active ingredients, proteins and peptides are encapsulated and easily handled by 
hydrogels . Because of their nature and different specifications, hydrogels can be 
used in many different types of controlled release systems. This unique diffusion-
controlled release mechanism as shown in Figure 2.16.  
 
Figure 2.16 : Hydrogels in controlled drug release systems [114]. 
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Hydrogels regulate the dissolution of encapsulated active ingredients (mostly 
amorphous) from the hydrogel matrix to maintain an elevated level of release for a 
prolonged period of time [114].  
2.4.8 Ion exchange resins controlled release systems 
Ion-exchange resins controlled release systems are produced to provide the 
controlled release of an ionic (or ionizable) active ingredients. The system is 
prepared by absorption of an ionized drug into the ion-exchange resin granules such 
as Amberlite, and consequently, particles are filtrated from the alcoholic medium; at 
final stage, the drug loaded granules are coated with a water permeable polymer, e.g. 
a modified copolymer of polyacrylic and methacrylic ester or homopolymer like 
PEG, and then spray drying the coated powders to handle the polymer capsulated 
drug resin preparation. 
Prolong drug release in long time and release efficiency of the ion-exchange resin 
controlled release systems depend on combination of the principle that positively or 
negatively charged pharmaceuticals with appropriate resins to yield insoluble 
polysalt resinates. Release mechanism for anionic and cationic ion-exchange 
resinates are demonstrated below [115].     
     
               
                        (2.3) 
        
                                       (2.4) 
                      
                                                (2.5) 
     
                                            (2.6) 
A cationic active ingredients are combined with an anionic ion-exchange resin e.g. a 
resin with a  SO3
-
 group. Hydronium ion (H
+
) in the gastrointestinal fluid penetrates 
to the durg material and activites the system for release of cationic drug from the 
core complex.  
An active ingredients are combined with a cationic ion exchange resin, e.g. a resin 
with a [N(CH3)3
+
] group. Chloride ion (Cl
-
) in the gastrointestinal fluid penetrates the 
to the durg material and activites the system for release of anionic drug from the core 
complex. 
39 
2.4.9 Release kinetics 
The mathematical models are used to evaluate the kinetics and mechanism of drug 
release from the microspheres that produced by us. The model that best fits the 
release data is selected based on the correlation coefficient (R
2
) value in various 
models and the highest  ‘R2’ value is considered as the best fit of the release data. 
Mathematical models are [116]: 
1) Zero order release model 
2) First order release model 
3) Hixson-Crowell release model 
4) Higuchi release model 
5) Korsmeyer – Peppas release model 
Zero order, as cumulative amount of drug released versus time, describes 
concentration-independent drug release rate from the formulation (Equation 1): 
                          (2.7) 
where k0 is the zero-order rate constant expressed in units of concentration/time and t 
is the time in hours. 
First order, as log cumulative percent drug remaining versus time, describes 
concentration-dependent drug release from the system (Equation 2): 
                                                 (2.8) 
where C0 is the initial concentration of drug and k is the first-order constant. 
Higuchi's model, as cumulative percentage of drug released versus square root of 
time, describes the release of drugs based on Fickian diffusion as a square root of 
time-dependent process from swellable insoluble matrix (Equation 3): 
                             (2.9) 
where k is the constant reflecting the design variables of the system. 
Hixson-Crowell cube root law, as the cube root of percentage drug remaining versus 
time, correlated the release from systems with polymer erosion/dissolution resulting 
in a change in surface area and diameter of particles or tablets (Equation 4): 
  
   
   
   
                       (2.10) 
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where Qt is the amount of drug released in time t, Q0 is the initial amount of the drug 
in the tablet, and kHC is the rate constant for the Hixson-Crowell rate equation. 
Korsmeyer-Peppas (Power Law) is derived a simple relationship which described 
drug release from a polymeric system (Equation 5).  
          
                                 (2.11) 
where Mt/M∞ is fraction of drug released at time t, kKP is the rate constant and n is the 
release exponent. To find out the mechanism of drug release, first 60% drug release 
data are fitted in Korsmeyer-Peppas model. The n value is used to characterize 
different release mechanisms as given in Table 2.2 for different shaped matrices. 
Table 2.2 : Exponent n and release mechanism of different geometries [116]. 
Exponent, n 
Drug release mechanism 
Thin Film Cylinder Sphere 
0.5 0.45 0.43 Fickian diffusion 
0.5 < n < 1.0 0.45 < n < 0.89 0.43 < n < 0.85 Anomalous transport 
1.0 0.89 0.85 Case-II transport 
> 1.0 > 0.89 > 0.85 Super Case-II transport 
    
Fickian diffusion refers to diffusion controlled release mechanism; on the other hand, 
anomalous diffusion or non-Fickian diffusion is obtained combination of both 
diffusion and erosion controlled rate release. Case-II transport or super case-II 
transport refers to the erosion of the polymeric chain. 
2.5 Spray Drying in Drug Delivery Systems 
Spray drying is a method of producing a dry powder from a liquid or slurry by 
rapidly drying with a hot gas. This is the preferred method of drying of many 
thermally sensitive materials such as foods and pharmaceuticals. A consistent 
particle size distribution is a reason for spray drying some industrial products such as 
catalysts. Air is the heated drying media; however, if the liquid is a flammable 
solvent such as ethanol or the product is oxygen-sensitive then nitrogen is used. 
Spray drying is one of the major industrial drying technologies. It is applied by many 
industries because of its ability to convert a liquid product into a dried powder in a 
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lenient single step; in addition, it allows to control to temperature and the particle 
formation process very accurately [117].    
2.5.1 Background of the spray drying process 
Briefly, a polymer solution is dropped (dispersed) into a hot air stream and the 
solvent (water) evaporates on the way to the bottom leaving a dried particle. The 
main advantage is the combination of particle formation and drying in one step. The 
disadvantages from the viewpoint of biological control are the variations in particle 
shape and size distribution, high temperatures and fast drying rates that normally do 
not allow for encapsulation of drying-sensitive living cells such as non-spore forming 
microbials [118]. Protectants and other additives may be added before or during the 
drying process. Especially in the food industry, spray-drying is used for the 
preservation and concentration of microorganisms. In biological control, too, spray 
drying is used to produce formulations with extended shelf-life. Figure 2.17 shows 
schematic presentation of a spray dryer. 
 
Figure 2.17 : Schematic diagram of the spray dryer used: (1) blower+air filter; (2) 
air compressor; (3) heater; (4) peristaltic pump; (5) temperature control; (6) inlet 
thermocouple; (7) atomizer: (a) compressed air; (b) feed microencapsulating 
composition; (8) drying chamber; (9) cyclone; (10) dry product collector [119]. 
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The solid is usually collected in a drum or cyclone. The liquid input stream is 
sprayed through an atomizer into a hot vapor stream and vaporized. Solids form as 
moisture quickly leaves the droplets. The atomization part is used to obtaine the 
desired characteristics by performing the optimum conditions to a dried powder for 
evaporation. Nozzles and rotary atomizers are used to form sprays. It is usually used 
to make the droplets as small as possible, maximizing heat transfer and the rate of 
water vaporization. Droplet sizes can range from 20 to 180 μm depending on the 
nozzle. There are two main types of nozzles: high-pressure single fluid nozzle (50 to 
300 bars) and two-fluid nozzles: one fluid is the liquid to dry and the second is 
compressed gas (generally air at 1 to 7 bars) [120].  
The central element of a spray dryer is the drying chamber. In drying chamber, the 
sprayed polymer solution is compared with hot gas (air or an inert gas), resulting in 
the evaporation of over 95% of the water contained in the droplets in a very limited 
times like seconds [120]. Droplet contact time with hot air and/or inert gas, contact 
angle are directly affected the properties of dried poweder such as particle shape and 
diameter. The type of contact (current, co-current and cross) between the spray and 
the air/inert gas is determined by the position of the atomizer relative to the hot 
air/inert gas. As a general orientation of the spray dryers, nozzle headers are located 
at the top of the dryer and spray down. 
Moisture evaporation (liquid chasing) takes place in two stages. During the first 
stage, saturation of wet droplet is performed by hot air/inert gas and the temperature 
of hot air/inert gas equals to bulb temperature. Evaporation takes a constant rate 
during drying stage and moisture in the drop to replace the liquid evaporated 
sufficiently [121]. After moisture of the droplet is reduced to nearly zero by hot 
air/inert gas, the second stage begins by production a dried shell to form at the 
surface.  At the following stage, evaporation depends on the diffusion of moisture 
through the shell that is increasing in thickness. Evaporation phase is dominant at the 
first stage and it falls rapidly during the second stage. Different polymer and/or 
composites have differing evaporation and particle-forming characteristics. On the 
other hand, solvent type of the polymers and/or composites results as same 
consequences mentioned before. The resulting particles may be uniform distributed 
spheres, or porous and irregularly shaped.  
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Following completion of drying, the particles of product must be separated from the 
hot drying air/inert gas [121]. The particles simply fall to the bottom of the chamber, 
so the separation is accomplished by the way. A small fraction of the particles may 
be remain entrained with the air and/or may be sticked together to the drying 
chamber of the spray dryer. Cyclones, bag filters, and electrostatic precipitators are 
the final separation stage equipments. Some spray dryers contain wet scrubbers that 
are often used to purify and cool the air so that it can be released to atmosphere. 
Reciprocating compressors of the spray dryers can be either stationary or portable, 
can be single or multi-staged, and can be driven by electric motors or internal 
combustion engines [121]. Small reciprocating compressors from 5 to 
30 horsepower (hp) are commonly seen in automotive applications and are typically 
for intermittent duty. Larger reciprocating compressors well over 1,000 hp (750 kW) 
are commonly found in large industrial and petroleum applications. Discharge 
pressures can range from low pressure to very high pressure (>18000 psi or 180 
MPa).  
Heaters in the spray dryers exist for all states of matter, including solids, liquids and 
gases and there are 3 types of heat transfer: Convection, Conduction and Radiation 
[121].  
2.5.2 Historical development of spray dryers 
From the 1870s through the early 1900s over a period of several decades, the 
development of spray drying equipment itself and drying techniques are revised and 
evolved [122]. The first spray dryer equipments are used nozzle atomizers, with 
rotary atomizers. Until the 1920s, because of many difficulties of continuous 
operation at spray dryers, commercial operations did not grow up and become 
profitable. On the other hand, commercial operations have just become profitable and 
practically feasible by the second decade of the twentieth century. First commercial 
applications are made at food industry such as milk powder production. After that, 
manufacturers are developed their designs and made spray dryers sophisticated to 
accommodate heat-sensitive products, emulsions and mixtures. Reduction of 
transportation expense by spray dryers at food and pharmaceutical industries, they 
became more popular during World War II. These improvements in spray drying led 
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to developments in the technology that greatly expanded the range of products like 
drugs and foods ingredients could be successfully spray dried [122]. 
Since early years, spray drying technology has developed tremendously and some of 
the major achievements have been to divide the drying process into several stages 
[123]. Integration of fluidized bed to the spray dryer provides to overcome problem 
of fluidization of moist solids at the entrance.     
2.5.3 Spray dryer types 
2.5.3.1 Co-Current flow spray dryers 
In a co-current dryer as seen in Figure 2.18, the hot air and fluid feed is entering the 
dryer chamber in the same direction [124]. The co-current flow enables the particles 
to have a lower residence time within the system, so heat-sensitive fluids are used 
easily in this system and the particle separator (typically a cyclone device) operates 
more efficiently.  
 
Figure 2.18 : Co-current flow spray dryer [121]. 
In the co-current flow system, spray evaporation is rapid, and the temperature of the 
drying air is reduced rapidly by the vaporization of solvent such as water, acetic acid, 
chloroform etc. 
2.5.3.2 Counter current flow spray dryers 
Counter-current spray dryers as seen in Figure 2.19, are used for the manufacture of 
thermally stable powders, such as detergents, and the fluid feed and hot air flowing 
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in opposite directions to each other into the drying chamber. Spray evaporation is 
rapid, heat transfer is more efficient [125].  
 
Figure 2.19 : Co-current flow spray dryer [121] 
A counter-current dryer offers more rapid evaporation, efficient heat transfer and 
more energy saving than a co-current design because the driest particles are in 
contact with hottest air, this design is not suitable for heat-sensitive products.  
2.5.3.3 Mixed flow spray dryers 
The gas flows down and the feed sprays up, and then comes down with the gas in 
mixed flow spray dryers (Figure 2.20). It allows for extra drying time, and 
decreasing the overall spray dryer height required; on the contrary, large particle size 
powders are produced by this way [121]. 
 
Figure 2.20 : Mixed flow spray dryer [121]. 
In the mixed flow systems, drying performance is not affected by product type or 
amount as so-current and/or counter current flow systems. However, thermally stable 
and resistant materials should be used due to the thermal degradation risk because the 
driest particles are exposed to the highest gas temperatures. 
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2.5.3.4 Open cycle spray dryers 
In an open cycle spray dryer as seen in Figure 2.21, is the most commonly used 
design. The drying air is drawn from the atmosphere, heated, sent to the drying 
chamber and then exhausted to the atmosphere. In brief, it is an open system. 
 
Figure 2.21 : Open-cycle spray dryer [126]. 
2.5.3.5 Closed cycle spray dryers 
Nitrogen gas as an inert atmosphere is usually used as hot gas in a closed-cycle spray 
dryers and nitrogen gas is circulated within the unit. Therefore, flammable organic 
solvents can be used in the drying chamber and solvent recovery is provided by this 
way.  
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Figure 2.22 : Closed-cycle spray dryer [126]. 
This system facilitates easy production of a solid dispersion, which can enhance the 
solubility and bioavailability of poorly water soluble solids. Figure 2.22 shows 
schematic view of a closed cycle spray dryer. 
2.5.3.6 Semi-closed cycle spray dryers 
Semi-closed cycle dryer design is a hybrid configuration of both open and closed 
cycle dryers and it is not air/inert gas tight. If odor is generated during drying, the 
small volumes of air vented from the system can be effectively and economically 
incinerated. Solvent recovery is also obtained, but less than closed system dryers. 
Figure 2.23 shows schematic view of a semi-closed cycle spray dryer. 
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Figure 2.23 : Semi-Closed-cycle spray dryer [126]. 
2.5.3.7 Single stage spray dryers 
One-stage drying is defined as the spray drying process where the product is dried to 
the final moisture content in the spray drying chamber, as shown in Figure 2.24. The 
basic and the most used system is a single stage co-current spray dryer with rotary or 
nozzle atomization.  
 
Figure 2.24 : Single stage spray dryer [127]. 
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2.5.3.8 Multi stage spray dryers 
The multi stage drier consists of a spray drier with an external vibrating fluid bed 
placed below the drying chamber. The product can be removed from the drying 
chamber with a higher moisture content, and the final drying takes place in the 
external fluid bed where the residence time of the product is longer and the 
temperature of the drying air lower than in the spray dryer. Consequently the two 
stage drying process was introduced which proved to be superior to the traditional 
single stage drying in terms of product quality and cost of production. Figure 2.25 
shows schematic view of a multi stage spray dryer. 
 
Figure 2.25 : Multi stage spray dryer [127]. 
2.5.3.9 Vertical spray dryers 
The air enters the spray dryer vertically through the air disperser at high velocity, 
ensuring optimal mixing of the atomized droplets with the drying air. The 
evaporation takes place instantaneously during the passage vertically down through 
the drying chamber. In this first stage drying, the particles are not completely dried. 
Vertical flow spray dryer is shown in Figure 2.26. 
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Figure 2.26 : Vertical spray dryer [128]. 
2.5.3.10 Horizontal spray dryers 
The horizontal type spray dryers are generally smaller than other dryers with the 
same capacity. The high-pressure pump in liquid feed system brings the liquid up to 
atomization pressure before the liquid is sprayed horizontal by a number of nozzles 
into the drying chamber. Horizontal flow spray dryer is shown in Figure 2.27. 
 
Figure 2.27 : Horizontal spray dryer [129]. 
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3. EXPERIMENTAL STUDIES 
3.1 Materials 
Polycaprolactone (Sigma-Aldrich): It is used to produce microspheres in polymer 
solutions.  It is obtained from Sigma-Aldrich and number average molecular weight 
(Mn) 10,000 g/mol and weight average molecular weight (Mw) 14,000 g/mol.  
Polyethylene glycol (Sigma-Aldrich): PEG-6000 type polyethylene glycol is used in 
polymer our studies and it is used to produce microspheres in solutions.   
Chitosan (Sigma-Aldrich): Medium molecular weight type chitosan is used in 
polymer solutions. 
Casein (Sigma-Aldrich): Casein from bovine milk is used in our studies and it is used 
to produce microspheres in polymer solutions.   
Sodium Alginate (Sigma-Aldrich): Alginic acid sodium salt from brown algae is 
used to produce microspheres in polymer solutions.   
L-Ascorbic acid (Sigma-Aldrich, ACS reagent, ≥99%):  L-Ascorbic acid is active 
ingredient in the drug delivery system. 
Acetic Acid (Merck, %100): Its mixture with formic acid is used to solve polymers 
to prepare encapsulation mixtures. 
Formic Acid (Merck, %98): Its mixture with acetic acid is used to solve polymers to 
prepare encapsulation mixtures. 
2,6-Dichloroindophenol sodium salt hydrate (Sigma-Aldrich): It (C12H6Cl2NNaO2 
xH2O) is a reagent for the titration of L-ascorbic acid. 
Oxalic acid (Merck, %99): It is an organic compound with the formula H2C2O4 and it 
is a colorless crystalline solid that forms a colorless solution in water. It is used to 
prepare stabilization solution to determine L-ascorbic acid in UV. 
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Phosphate buffer solution (PBS) is a buffer solution commonly used in biological 
research. It is a salty solution containing sodium phosphate, sodium chloride and 
potassium phosphate. The buffer helps to maintain a constant pH. 
0.1 M Acetic Acid PBS, pH 2.8: It is used for drug release fluid in our studies. To 
prepare 0.1 M PBS at pH 2.8; 2.86 ml glacial acetic acid is dissolved in 350 ml 
water. Volume is completed to 0.5 L with 1 M HCl and 1 N NaOH is used to adjust 
pH at 2.8.      
0.1 M PBS, pH 7.4: It is used for drug release fluid in our studies. To prepare 0.1 M 
PBS at pH 7.4; 0.26 g KH2PO4, 2.17 g Na2HPO4.7H2O and 8.71 g NaCl are 
dissolved in 800 ml water. Volume is completed to 1 L with 1 M HCl and 1 N NaOH 
is used to adjust pH at 7.4.      
0.1 M NaHCO3 PBS, pH 9.6: It is used for drug release fluid in our studies. To 
prepare 0.1 M PBS at pH 9.6; 4.2 g NaHCO3 is dissolved in 350 ml water. Volume is 
completed to 0.5 L with 1 M HCl and 1 N NaOH is used to adjust pH at 9.6.      
3.2 Equipments 
3.2.1 Spray dryer  
Yamato ADL 310 lab scale spray dryer (seen in Figure 3.1) to obtain microspheres.  
 
Figure 3.1 : Yamato ADL 310 lab scale spray dryer [130]. 
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Table 3.1 also shows specifications of Yamato ADL 310 type lab scale spray dryer 
[130].   
Table 3.1 : Specifications of spray dryer [130]. 
Evaporation Capacity Maximum 1300 ml/h 
Temperature Control Range 40 
o
C – 200 oC 
Dry Air Flow Rate Maximum 0.7 m
3
/min 
Feed Flow Rate Maximum 28 ml/min 
Spray Nozzle Only for Liquid and Air 
3.2.2 Particle size analyzer  
Malvern Mastersizer 2000 is used to obtain particle size diameter and its distribution. 
Two procedures are involved in measuring a sample on the Mastersizer; first, as 
shown in Figure 3.2, there is the capturing of the scattering pattern from the sample 
by optical unit and this is known as the “measurement” [131]. 
 
Figure 3.2 : Basic Optical System of a Laser Diffraction Particle Size Analyzer 
[131]. 
The detector within the optical unit is made up of many individual detectors. Each 
detector is collect the light scattering from a particular range of angles. Second, once 
the Malvern software is used to analyze the measurement which is completed in the 
first stage and the raw data contained. 
3.2.3 Scanning electron microscopy  
Scanning Electron Microscopy (SEM, Model: Jeol, JSM-6390 LV) is used to obtain 
morphological structures of microspheres. SEM (in Figure 3.3) uses a focused beam 
of high-energy electrons to generate a variety of signals at the surface of solid 
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specimens [132]. The signals that derive from electron-sample interactions reveal 
information about the sample including external morphology (texture), chemical 
composition, and crystalline structure and orientation of materials making up the 
sample. Particle diameters and the morphology are determined by this way.    
 
Figure 3.3 : Schematic drawing of SEM [132]. 
3.2.4 Thermogravimetric analysis 
Thermogravimetric analysis or thermal gravimetric analysis (TGA, Perkin-Elmer 
Diamond TG/DTA) is used to analyze microsphere structure. Thermogravimetric 
Analysis is a technique in which the mass of a substance is monitored as a function 
of temperature or time as the sample specimen is subjected to a controlled 
temperature program in a controlled atmosphere [133]. Figure 3.4 shows a typical 
TGA instrument schematic view. 
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Figure 3.4 : Schematic of a typical TGA [133]. 
In our study, the microsphere sample is placed in furnace and it is burned in the N2 
atmosphere without O2 with the ramp 30 
o
C/min up to 800 
o
C. TGA scan is obtained 
from the measurement to determine decomposition temperature and char yield.  
3.2.5 Ultraviolet analysis 
Ultraviolet Analysis (UV, Model: UV Mini 1240 SHIMADZU, Single Beam) is used 
to determine drug encapsulation efficiency and drug release ratios.  
 
Figure 3.5 : Schematic diagram of a fixed-wavelength single-beam 
spectrophotometer [134]. 
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The simplest spectrophotometer is a single-beam instrument equipped with a fixed-
wavelength monochromator as seen in Figure 3.5 [134]. The instrument is calibrated 
to 0% T while using a shutter to block the source radiation from the detector. After 
opening the shutter, the instrument is calibrated to 100% T using an appropriate 
blank. The blank is then replaced with the sample and its transmittance measured.  
3.2.6 Other equipments 
Other equipments that are used in our studies are listed below: 
 Magnetic stirrer, Ikamag RH  
 Oven, Binder  
 Heater, Ikamag RCT Classic  
 Analytical balance, And, Gr-200  
 Shaking water bath, Juloba SW 22  
 pH meter, Inolab WTW 
3.3 Methods 
3.3.1 Preparation of polymer mixture 
PCL+PEG+CH, PCL+PEG+CS, and PCL+PEG+SA polymer mixture solutions are 
prepared by acetic acid-formic acid solutions with 3:7 (v/v) ratios for ∼24 h, 
followed by a filtration step (1.5 μm; 934 AH® Binderless Glass Microfiber Filter 
Media). The value of 3:7 (v/v) acetic acid:formic acid is determined  by  previous  
studies [26, 135, 136]. Polymer amounts are 10 wt% and mixtures are prepared by 
1:1:1 (wt/wt/wt) ratio. 
3.3.2 L-Ascorbic acid determination procedure 
L-ascorbic acid determination procedure is based on the 2,6-dichloroindophenol 
sodium salt titration method [137]. Firstly, 100 mg L-ascorbic acid is dissolved in 
100 ml, 0.4 wt% oxalic acid stabilizer solution to determine calibration curve. The 
stock L-ascorbic acid solution is treated by 2,6-dichloroindophenol sodium salt. The 
method of quantitative determination is based on selective oxidation of L-ascorbic 
acid to dehydroascorbic acid with 2,6-diclorphenolindophenol as seen in Figure 3.6. 
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Figure 3.6 : L-ascorbic acid reduction by the oxidized dye the 2,6-
dichloroindophenol  [138]. 
Oxidized different L-ascorbic acid stock solutions with the 2,6-dichloroindophenol 
are analyzed by UV at 518 nm. On the other hand, standard blind solutions are 
prepared and absorbance values of 2,6-diclorphenolindophenol solutions are also 
determined at 518 nm. Absorbance values between L-ascorbic acid stock solutions 
and 2,6-diclorphenolindophenol solutions are subtracted and calibration curve are 
prepared. Figure 3.7 shows calibration curves of L-ascorbic acid solutions at 518 nm.  
 
Figure 3.7 : Calibration curve of L-ascorbic acid solutions. 
3.3.3 Drying studies 
Although in industrial spray drying processes, dispersions with high solid 
concentration are recommended (>30%) to reduce the costs and increasing drying 
efficiency, in this study dispersions with low concentration of total solids are selected 
in order to avoid obstruction of the pneumatic nozzle when using blends with the 
highest concentration of gum [139].  
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Polymer solutions are fed to spray dryer (Yamato ADL 310 lab scale spray dryer) by 
a peristaltic pump and first of all, best drying conditions are determined by changing 
drying temperature (120 
o
C, 135 
o
C, and  150 
o
C) and feed flow rate (3  mL/min,  6 
mL/min,  and  9 mL/min). Atomizer pressure is constant at 1 barg. Drying efficiency 
is calculated by Equation 3:1: 
                           
                     
                              
                 (3.1) 
3.3.4 Drug encapsulation studies 
Particle diameter and particle size distribution are determined and L-ascorbic acid in 
different weight ratios are loaded to the microspheres that have the lowest particle 
diameter. L-ascorbic acid loading studies are done by indirect loading (pH 7.0) of 
drug to microspheres at 25 
o
C and 200 rpm.  L-ascorbic acid solutions are 5 wt%, 10 
wt%, and 15 wt%, respectively. Encapsulation efficiency is calculated by Equation 
3:2 [22]: 
                           
                             
                               
                      (3.2) 
Liquid phase is analyzed by UV at 518 nm to calculate Equation 3:2 [140].  
3.3.5 Drug release studies 
Calculations in drug release step of the study are also performed by UV. 0.5 mg 
blend/1 mL release medium with different pH PBS solutions (pH 2.8, 7.4, and 9.6) 
ratio is used. Polymeric drug is dispersed in the release medium and incubation 
occurred at 25 °C with shaking. Drug release is calculated by Equation 3:3 [22]. 
               
     
     
                   (3.3) 
where; 
C(t) refers to drug amount in any time and C(0) to drug amount at t=0.   
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4. RESULTS AND DISCUSSIONS 
4.1 PCL+PEG+CH Encapsulation Systems 
Yields and particle size distributions with standard deviation are shown for all 
studies in Figure 4.1 and Figure 4.2, respectively. Due to the Figure 4.2, Metasizer 
analyses are done 3 times and particle diameter distribution is determined by 
standard deviation of the results. Final values demonstrate particle size (µm) with 
standard mean of PCL-PEG-CH microspheres. Figure 4.1 determines that drying 
efficiency increase by decreasing of flow rates at 120 
o
C and 135 
o
C; on the contrary 
drying efficiency increase by increasing of flow rate at 150 
o
C.  The  reason  of  these  
results  is  that  increasing  drying  temperature resulted in agglomeration of polymer 
mixture, so contact  time with polymer mixture and drying  temperature had 
adversely effect on diameter distribution [22]. Due to these results, 120 
o
C and 3 
ml/min are the best drying conditions because of the lowest particle diameter with 
19,143±0,023 µm and highest surface area with 0.897 m2/g surface area in this study.    
 
Figure 4.1 : Yield (wt%) at different drying temperature (
o
C) and flow rates 
(ml/min). 
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Figure 4.2 : Particle diameter (µm) with standard deviations at different drying 
temperature (
o
C) and flow rates (ml/min). 
SEM micrographs are shown in Figure 4.3 for 120 
o
C-3 ml/min, 135 
o
C-3 ml/min, 
and 150 
o
C-9 ml/min.  It is easily seen that agglomeration increases by increasing of 
drying temperature. Porous structure of microsphere is also easily shown in all SEM 
micrographs. This porous structure is an advantage because drug loading capacity of 
porous spheres is higher than other spherical structures [16].   
 
Figure 4.3 : SEM micrographs (a) 120 
o
C, 3 ml/min; (b) 135 
o
C-3 ml/min; (c) 150 
o
C, 9 ml/min. 
The sample is placed in furnace and it is burned in the N2 atmosphere without O2 
with the ramp 30 
o
C/min up to 800 
o
C. TGA scan is obtained from the measurement 
to determine decomposition temperature and char yield. TGA curves for PCL-PEG-
CH bio-blend and L-ascorbic acid loaded bio-blend are shown in Figure 4.4 and 
Figure 4.5, respectively.  
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Figure 4.4 : TGA of PCL-PEG-CH microsphere at 120 
o
C, 3 ml/min. 
It is easily seen that TGA curves in Figure 4.4 and Figure 4.5 are blends because 
thermal degradation curves goes down step by step. Figure 4 illustrates PCL-PEG-
CH blend thermal degradation and it begins about 300 
o
C with CH degradation, 
following at 350 
o
C with PCL degradation and finalized at 400 
o
C with PEG-6000 
degradation. L-ascorbic acid (Figure 4.5) shows that the decomposition starts at 
around 190 °C. Four thermal degradation steps are identified and allocated to the L-
ascorbic acid and polymer fractions, respectively, based on the TGA curves.  
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Figure 4.5 : TGA curve of L-ascorbic acid loaded microsphere. 
Drug release studies are performed under three different L-ascorbic acid 
concentrations (5 wt%, 10 wt%, and 15 wt%) with different loading time and PCL-
PEG-CH  particle  amounts. Microsphere obtained  at  120 
o
C  and  3 ml/min is used  
in drug  loading studies because this microsphere had the lowest particle diameter 
and also best distributed  particles due to  the Metasizer  analyses (see also in Figure 
4.1 and 4.2). Results are shown in Figure 4.6 and Figure 4.7 for effects of loading 
time and effects of particle amount, respectively.  All measurements are carried in 
triplicate and values are presented as the mean ± standard deviation (SD). 
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Figure 4.6 : Effects of drug loading time for L-ascorbic acid on PCL-PEG-CH. 
 
Figure 4.7 : Effects of particle amount for L-ascorbic acid loading on PCL-PEG-CH. 
Drug loading experiments are carried out at 25 
o
C and 200  rpm and Figure 4.6 
demonstrates that L-ascorbic acid concentrations are rapidly increased  in 2 h and 
stabilized from 2 h to 4 h. We achieved significant results in this part and L-ascorbic 
acid loading is 99.13 wt% due to UV results. SD values are calculated ±3.0, ±2.0 and 
±1.0 for drug loading environment at 5 wt%, 10 wt% and 15 wt% L-ascorbic acid 
solutions, respectively.  
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We  also  determined  the  effects  of  particle  amount  on  drug  loading  efficiency  
by changing particle amounts from 0.5 mg to 2 mg by  increasing of 0.5. Results are 
showed in Figure 4.7. 0.5 mg PCL-PEG-CH in 15 wt% L-ascorbic acid experiment is 
the most effective study. We also revealed that increasing particle amount decreased 
drug loading efficiency. The explanation of the result is that increasing particle 
amount concluded agglomeration of microspheres, so particle surface area is 
decreased and it affected drug loading efficiency in bad direction. SD values are 
calculated ±3.0, ±2.0 and ±1.0 for drug loading environment at 5 wt%, 10 wt% and 
15 wt% L-ascorbic acid solutions, respectively. 
Drug release studies are performed for the most loaded microsphere obtained in 15 
wt% L-ascorbic acid solution by 0.5 mg particle amount. Drug release studies are 
obtained at three different release medium by changing pH from 2.8 to 9.6 and result 
are shown in Figure 4.8. 
 
Figure 4.8 : Drug release studies at different release mediums in 8 hours. 
We achieved peak release points in just 2 hours in release mediums and Figure 4.8 
also illustrated that decreasing pH increased drug release efficiency. Drug loaded 
microspheres contains PCL-PEG-CH bio-based polymers and particularly interaction 
of PCL and CH in acidic medium is better than higher pH values [141]. By this way, 
L-ascorbic acid release remarkably increased in pH 2.8 (max. 93.18%) as shown in 
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the figure above. SD values are calculated ±3.0, ±2.0 and ±3.0 for drug loading 
environment at pH 2.8, pH 7.4 and pH 9.6 release mediums, respectively. 
To describe drug release mechanism more precisely, there is a more comprehensive 
but still  very  simple  semi-empirical  formulations,  called  zero  order  kinetics,  
first  order kinetics, Higuchi, Hixson-Cromwell, and  the Korsmeyer-Peppas power  
law [142, 143]. Thus, the drug release data are fitted to these kinetic models to 
analyze the release kinetics and the mechanism from the polymeric drugs. Based on 
the best correlation coefficient values, the most appropriate model is selected to 
explain the release behavior of the drug. Drug release kinetics are illustrated with 
different kinetic models at pH 2.8, pH 7.4, pH 9.6 as seen in Figure 4.9, Figure 4.10, 
and Figure 4.11, respectively.  The values of the release exponent (n), kinetic rate 
constant (k) and the correlation coefficient (R
2
) are tabulated in the Table 4.1. L-
ascorbic acid release from microparticles exhibits very high correlation with the 
Korsmeyer–Peppas semi empirical model, with R2 > 0.98. The values of “n” 
determined by the Korsmeyer–Peppas semi empirical model, ranged from 1.0008 to 
1.2475 as tabulated in the Table 4.1. The results indicate that the formulations exhibit 
super case-II transport mechanism (n>0.85), so the drug release is governed by non-
Fickian diffusion, the dominant mechanism for drug transport is due to polymer 
relaxation as the gels swells [144].  
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Figure 4.9 : L-ascorbic acid release kinetics at pH 2.8 with different models from the PCL-PEG-CH microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Figure 4.10 : L-ascorbic acid release kinetics at pH 7.4 with different models from the PCL-PEG-CH microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Figure 4.11 : L-ascorbic acid release kinetics at pH 9.6 with different models from the PCL-PEG-CH microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Table 4.1 : Kinetic parameters of L-ascorbic acid release from the PCL-PEG-CH. 
pH 
Zero-order First-order Higuchi Hixson-Crowell Korsmeyer-Peppas 
k0  
(min
-1
) 
R
2
 
k1  
(min
-1
) 
R
2
 
kH  
(min
-1/2
) 
R
2
 
kHC  
(min
-1
) 
R
2
 n R
2
 
kHP  
(min
-n
) 
2.8 0.0714 0.9248 0.0046 0.9351 2.2771 0.8710 0.0037 0.9346 1.0008 0.9821 0.0082 
7.4 0.1169 0.9937 0.0037 0.9306 3.8521 0.9996 0.0038 0.9585 1.1577 0.9973 0.0037 
9.6 0.1293 0.9859 0.0024 0.9411 4.2692 0.9956 0.003 0.9597 1.2475 0.9896 0.0019 
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4.2. PCL+PEG+CS Encapsulation Systems 
Yield and particle size distribution with standard deviation are shown for all studies 
in Figure 4.12 and Figure 4.13, respectively. Due to the Figure 4.13, Mastersizer 
analyses are done 3 times and particle diameter distribution is determined by 
standard deviation of the results. Final values demonstrate particle size (µm) with 
standard deviation of PCL-PEG-CS microspheres. Figure 4.12 determines that drying 
efficiency increase by decreasing of flow rates at 120 
o
C, 135 
o
C and 150 
o
C. The 
cause of these results are that increasing drying  temperature resulted in 
agglomeration of polymer mixture, so contact  time with polymer mixture and drying  
temperature had adversely effect on diameter distribution [145]. Due to these results, 
135 
o
C  and  3  ml/min are  the  best  drying  conditions  because  the  lowest particle 
diameter and highest surface area are also obtained with 27.540±0.656 µm particle 
size with 0.512 m
2
/g surface area in this study. The yields from spray drying have 
also been significantly decreased at higher flow rates due to the less contact time 
with hot drying air [146].  
 
Figure 4.12 : Yield (wt%) at different drying temperature (
o
C) and flow rates 
(ml/min). 
Figure 4.12 shows the tendency of the yield to be higher when the spray rate was 
low. Additionally, particle size diameters are increased at higher spray rates as seen 
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in Figure 4.13. It is revealed that we have to avoid higher spray rates because of its 
reverse effect on encapsulation material.   
 
Figure 4.13 : Particle diameter (µm) with standard deviations at different drying 
temperature (
o
C) and flow rates (ml/min). 
SEM micrographs are shown in Figure 4.14 for PCL-PEH-CS microsphere obtained 
at 135 
o
C and 3 ml/min.   
 
(a)                                 (b)                   (c) 
Figure 4.14 : SEM micrographs of PCL-PEH-CS microsphere (a) 5,000X; (b) 
9,000X; (c) 10,000X. 
Observing the external morphology, particles show a porous and spherical-like shape 
and various sizes with no apparent cracks or fissures, which is an advantage, since it 
implies that capsules have higher surface area and permeable for active ingredient 
(L-ascorbic acid). The variety in size is a typical characteristic of particles produced 
by spray drying. However, we can say that particles are distributed homogeneously 
as seen in Figure 4.14. The mixtures of different wall materials are influenced on 
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microparticles morphology [147, 148].  As well, the picture shows that there are no 
agglomeration and adherence between microspheres during drying process. 
TGA curve for PCL-PEG-CS bio-blend is shown in Figure 4.15. The sample is 
placed in furnace and it is burned in the N2 atmosphere without O2 with the ramp 30 
o
C/min up to 800 
o
C. TGA scan is obtained from the measurement to determine 
decomposition temperature and char yield.  
When heating a ternary blend (PCL-PEG-CS), three well-separated peaks are 
obtained on the TGA thermogram as shown in Figure 4.15. Customarily, the peak 
temperatures are referred to the degradation temperatures of the blending 
components [149]. Figure 4.15 shows encapsulation material thermal degradation 
and it begins about 200 
o
C with CS degradation, following at 350 
o
C with PCL 
degradation and finalized at 400 
o
C with PEG-6000 degradation.  
 
Figure 4.15 : TGA of PCL-PEG-CS microsphere obtained at 135 
o
C, 3 ml/min. 
Drug encapsulation studies are performed under three different L-ascorbic acid 
concentrations (5 wt%, 10 wt%, and 15 wt%)  at pH 7.0 with different loading time 
and PCL-PEG-CS  particle  amounts. It is expected that encapsulation efficiency of a 
drug changes depending on structures of the microspheres [150]. Particle diameter 
also affects the encapsulation efficiency. Drug-encapsulated amount depends on 
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surface area of the microspheres. Microsphere obtained  at  135 
o
C  and  3 ml/min is 
used  in drug  loading studies because this microsphere had the lowest particle 
diameter and also best distributed  particles due to  the Mastersizer  analyses (see 
also in Figure 4.12 and 4.13). Figure 4.16 and Figure 4.17 indicate that how much L-
ascorbic acid is encapsulated due to the time and particle amount, respectively. All 
measurements are carried in triplicate and values are presented as the 
mean ± standard deviation (SD). 
Figure 5 shows drug absorbance is achieved peak value (84.05% loading efficiency) 
in one hour; thereafter it is smoothly decreased in all L-ascorbic acid solutions. SD 
values are calculated ±4.0, ±2.5 and ±1.5 for drug loading environment at 5 wt%, 10 
wt% and 15 wt% L-ascorbic acid solutions, respectively.  
 
Figure 4.16 : Effects of drug loading time on encapsulation of L-ascorbic acid. 
Although there is no significant difference, Figure 6 indicates that the encapsulation 
efficiency tended to increase from 0.5 to 2.0 mg particle/mL L-ascorbic acid 
solution. On the contrary, increasing weight percent of L-ascorbic acid in solution 
significantly increased loading rates. It changes from 49.93% to 84.05% by PCL-
PEG-CS microsphere amounts from 0.5 to 2.0 mg particle/mL solution. It is also 
facts that low diameter and well distributed structure of microspheres are reasons to 
gain high L-ascorbic acid loading values [151].  Thus, when highly water-soluble 
drugs, such as L-ascorbic acid, are encapsulated using ternary polymer blends, % 
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encapsulations achieved are expectably high. SD values are calculated ±5.0, ±2.9 and 
±1.5 for drug loading environment at 5 wt%, 10 wt% and 15 wt% L-ascorbic acid 
solutions, respectively. 
In-vitro release profiles of L-ascorbic acid from the microspheres produced by PCL-
PEG-CS are shown in Figure 4.18. Experimental uncertainties in the % drug 
released, based on three replicates, are approximately changed from 3.4% to 5.7%.  
 
Figure 4.17 : Effects of particle amount on encapsulation of L-ascorbic acid. 
 
Figure 4.18 : L-ascorbic acid release with different pH mediums in 8 hours. 
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The % drug release initially in 2 h is 17.21 ± 3.36 at pH 2.8, 13.84 ± 3.50 at pH 7.4 
and 33.39 ± 5.7 at pH 9.6. Maximum drug release ratio achieved in 6 h is 68.21 ± 5.7 
at pH 9.6. The results indicate that L-ascorbic acid in the bioblend based 
microspheres are easily degraded higher pH values particularly at basic scale. 
Previous studies are showed that casein is soluble at basic pH values because of this 
reason L-ascorbic acid release are more effective at pH 9.6 [152]. In additionally, 
since CS degraded L-ascorbic acid release is increased, it also indicates CS and L-
ascorbic acid interaction is stronger than PCL and PEG. Due to the previous studies, 
our experiments showed that results are very encouraging particularly with high drug 
release ratio for a new L-ascorbic acid delivery drugs by PCL-PEG-CS microsphere 
[153-155].   
To describe drug release mechanism more precisely, there is a more comprehensive 
but still  very  simple  semi-empirical  formulations,  called  zero  order  kinetics,  
first  order kinetics, Higuchi, Hixson-Cromwell, and  the Korsmeyer-Peppas power  
law  [142, 143]. Thus, the drug release data are fitted to these kinetic models to 
analyze the release kinetics and the mechanism from the polymeric drugs. Based on 
the best correlation coefficient values, the most appropriate model is selected to 
explain the release behavior of the drug. Drug release kinetics are illustrated with 
different kinetic models at pH 2.8, pH 7.4, pH 9.6 as seen in Figure 4.19, Figure 
4.20, and Figure 4.21, respectively. The values of the release exponent (n), kinetic 
rate constant (k) and the correlation coefficient (R
2
) are tabulated in the Table 4.2. L-
ascorbic acid release from microparticles exhibits high correlation with the 
Korsmeyer–Peppas semi empirical model, with R2 > 0.94. The values of “n” 
determined by the Korsmeyer–Peppas semi empirical model, ranged from 0.259 to 
0.553 as tabulated in the Table 4.2. The results  indicate that the formulations at pH 
2.8 and pH  7.4  exhibit  Fick  diffusion  mechanism  (n<0.5),  so  the  drug  release  
is  governed  by diffusion.  The formulation at pH 9.6 exhibits anomalous transport 
(i.e non-Fickian diffusion mechanism), so the drug release is governed by both 
diffusion of the drug and dissolution of the polymeric network [143].
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Figure 4.19 : L-ascorbic acid release kinetics at pH 2.8 with different models from the PCL-PEG-CS microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Figure 4.20 : L-ascorbic acid release kinetics at pH 7.4 with different models from the PCL-PEG-CS microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
78 
 
Figure 4.21 : L-ascorbic acid release kinetics at pH 9.6 with different models from the PCL-PEG-CS microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Table 4.2 : Kinetic parameters of L-ascorbic acid release from the PCL-PEG-CS. 
pH 
Zero-order First-order Higuchi Hixson-Crowell Korsmeyer-Peppas 
k0  
(min
-1
) 
R
2
 
k1  
(min
-1
) 
R
2
 
kH  
(min
-1/2
) 
R
2
 
kHC  
(min
-1
) 
R
2
 n R
2
 
kHP  
(min
-n
) 
2.8 0.0204 0.9209 0.0003 0.9210 0.6767 0.9396 0.0004 0.9210 0.2588 0.9471 0.0493 
7.4 0.0376 0.9588 0.0005 0.9607 1.2403 0.9682 0.0007 0.9601 0.4960 0.9733 0.0127 
9.6 0.1014 0.8866 0.0022 0.9107 3.4266 0.9371 0.0026 0.9044 0.5526 0.9586 0.0246 
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4.3 PCL+PEG+SA Encapsulation Systems 
As the last part of the study, yield of PCL-PEG-SA experiments is shown in Figure 
4.22. Peak points are shown at 3 ml/min, 9 ml/min, and 6 ml/min flow rates at 120 
o
C, 135 
o
C, and 150 
o
C, respectively. It seems low flow rate is more effective at low 
drying temperature; on the other hand, flow rate is increased efficiency is decreased. 
 
Figure 4.22 : Yield (wt%) at different drying temperature (
o
C) and flow rates 
(ml/min). 
Figure 4.23 shows particle distribution with standard deviations for PCL-PEG-SA 
studies and the lowest particle diameter and the highest surface area are obtained at 
120 
oC and 9 ml/min drying conditions with 37.924±0.416 µm particle size with 
0.461 m
2
/g surface area. Although microparticle yield is low at higher flow rates, 
particle diameter is getting decreased significantly due to the less contact time with 
hot drying air. 
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Figure 4.23 : Particle diameter (µm) with standard deviations at different drying 
temperature (
o
C) and flow rates (ml/min). 
SEM micrographs are shown in Figure 4.24 for PCL-PEH-SA microsphere obtained 
at 120 
o
C and 9 ml/min.   
 
Figure 4.24 : SEM micrographs of PCL-PEH-SA microsphere (a) 5,000X; (b) 
12,000X; (c) 7,000X. 
Observing the external morphology, particles show a porous and spherical shape and 
various sizes with no apparent cracks or fissures, which is an advantage, since it 
implies that capsules have higher surface area and permeable for active ingredient 
(L-ascorbic acid). The mixtures of different wall materials are influenced on 
microparticles morphology.  As well, the picture shows that there are no 
agglomeration and adherence between microspheres during drying process. 
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TGA curve for PCL-PEG-SA microspheres is shown in Figure 4.25. The sample is 
placed in furnace and it is burned in the N2 atmosphere without O2 with the ramp 30 
o
C/min up to 800 
o
C. TGA scan is obtained from the measurement to determine 
decomposition temperature and char yield.  
When heating a ternary blend (PCL-PEG-SA), three well-separated peaks are 
obtained on the TGA thermogram as shown in Figure 4.25. Customarily, the peak 
temperatures are referred to the degradation temperatures of the blending 
components. Figure 4.25 shows encapsulation material thermal degradation and it 
begins around 180-200 
o
C with SA degradation, following at 350 
o
C with PCL 
degradation and finalized at 400 
o
C with PEG-6000 degradation.  
 
Figure 4.25 : TGA of PCL-PEG-SA microsphere obtained at 120 
o
C, 9 ml/min. 
Drug encapsulation studies are performed under three different L-ascorbic acid 
concentrations (5 wt%, 10 wt%, and 15 wt%)  at pH 7.0 with different loading time 
and PCL-PEG-SA  particle  amounts. It is expected that encapsulation efficiency of a 
drug changes depending on structures of the microspheres. Particle diameter also 
affects the encapsulation efficiency. Drug-encapsulated amount depends on surface 
area of the microspheres. Microsphere obtained at 120 
o
C and 9 ml/min is used in 
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drug loading studies because this microsphere had the lowest particle diameter and 
also best distributed particles due to the Mastersizer analyses (see also in Figure 4.22 
and Figure 4.23). Figure 4.26 and Figure 4.27 indicate that how much L-ascorbic 
acid is encapsulated due to the time and particle amount, respectively. All 
measurements are carried in triplicate and values are presented as the 
mean ± standard deviation (SD). 
Figure 4.26 shows drug absorbance is achieved peak value (82.57% loading 
efficiency) in one hour; thereafter it is smoothly decreased in all L-ascorbic acid 
solutions. SD values are calculated ±5.4, ±4.7 and ±2.7 for drug loading environment 
at 5 wt%, 10 wt% and 15 wt% L-ascorbic acid solutions, respectively.  
 
Figure 4.26 : Effects of drug loading time on encapsulation of L-ascorbic acid. 
Although there is no significant difference, Figure 4.27 indicates that the 
encapsulation efficiency tended to increase from 0.5 to 2.0 mg particle/mL L-
ascorbic acid solution. On the contrary, increasing weight percent of L-ascorbic acid 
in solution significantly increased loading rates. It changes from 43.26% to 82.57% 
by PCL-PEG-SA microsphere amounts from 0.5 to 2.0 mg particle/mL solution. It is 
also facts that low diameter and well distributed structure of microspheres are 
reasons to gain high L-ascorbic acid loading values.  Thus, when highly water-
soluble drugs, such as L-ascorbic acid, are encapsulated using ternary polymer 
mixtures, % encapsulations achieved are expectably high. SD values are calculated 
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±5.4, ±7.8 and ±5.5 for drug loading environment at 5 wt%, 10 wt% and 15 wt% L-
ascorbic acid solutions, respectively. 
 
Figure 4.27 : Effects of particle amount on encapsulation of L-ascorbic acid. 
In-vitro release profiles of L-ascorbic acid from the microspheres produced by PCL-
PEG-SA are shown in Figure 4.28. Experimental uncertainties in the % drug 
released, based on three replicates, are approximately changed from 1.4% to 4.4%.  
The % drug release initially in 2 h is 5.00 ± 4.35 at pH 2.8, 11.00 ± 3.23 at pH 7.4 
and 6.76 ± 1.41 at pH 9.6. Maximum drug release ratio achieved in 6 h is 34.27 ± 
1.41 at pH 7.4. The results indicate that L-ascorbic acid in the PCL-PEG-SA 
microspheres are easily degraded nearly neutral pH values. Previous studies are 
showed that SA is soluble at neutral pH values because of this reason L-ascorbic acid 
release are more effective at pH 7.4. In additionally, since SA degraded L-ascorbic 
acid release is increased, it also indicates SA and L-ascorbic acid interaction is 
stronger than PCL and PEG. Due to the previous studies, our experiments showed 
that results are very encouraging particularly with high drug release ratio for a new 
L-ascorbic acid delivery drugs by PCL-PEG-CS based blends.   
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Figure 4.28 : L-ascorbic acid release with different pH mediums in 8 hours. 
To describe drug release mechanism more precisely, there is a more comprehensive 
but still  very  simple  semi-empirical  formulations,  called  zero  order  kinetics,  
first  order kinetics, Higuchi, Hixson-Cromwell, and  the Korsmeyer-Peppas power  
law  [142, 143]. Thus, the drug release data are fitted to these kinetic models to 
analyze the release kinetics and the mechanism from the polymeric drugs. Based on 
the best correlation coefficient values, the most appropriate model is selected to 
explain the release behavior of the drug. Drug release kinetics are illustrated with 
different kinetic models at pH 2.8, pH 7.4, pH 9.6 as seen in Figure 4.29, Figure 
4.30, and Figure 4.31, respectively. The values of the release exponent (n), kinetic 
rate constant (k) and the correlation coefficient (R
2
) are tabulated in the Table 3.3. L-
ascorbic acid release from microparticles exhibits high correlation with the 
Korsmeyer–Peppas semi empirical model, with R2 > 0.82. The values of “n” 
determined by the Korsmeyer–Peppas semi empirical model, ranged from 0.8152 to 
1.1075 as tabulated in the Table 4.3. The results indicate that the formulations at pH 
2.8 and pH 9.6 exhibit super case-II transport mechanism (n>0.85), so the drug 
release is governed by non-Fickian diffusion, the dominant mechanism for drug 
transport is due to polymer relaxation as the gels swells [144]. On the other hand, the 
formulation at pH 7.4 exhibits anomalous transport, so the drug release is governed 
by both diffusion of the drug and dissolution of the polymeric network [143]. 
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Figure 4.29 : L-ascorbic acid release kinetics at pH 2.8 with different models from the PCL-PEG-SA microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Figure 4.30 : L-ascorbic acid release kinetics at pH 7.4 with different models from the PCL-PEG-SA microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Figure 4.31 : L-ascorbic acid release kinetics at pH 9.6 with different models from the PCL-PEG-SA microspheres (a) Zero-order (b) First-order 
(c) Higuchi (d) Hixson-Cromwell (e) Korsmeyer-Peppas. 
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Table 4.3 : Kinetic parameters of L-ascorbic acid release from the PCL-PEG-SA. 
pH 
Zero-order First-order Higuchi Hixson-Crowell Korsmeyer-Peppas 
k0  
(min
-1
) 
R
2
 
k1  
(min
-1
) 
R
2
 
kH  
(min
-1/2
) 
R
2
 
kHC  
(min
-1
) 
R
2
 n R
2
 
kHP  
(min
-n
) 
2.8 0.0466 0.8027 0.0005 0.8033 1.5917 0.8680 0.0008 0.8032 1.1075 0.9042 0.0003 
7.4 0.0602 0.7802 0.0008 0.7599 2.0324 0.8231 0.0011 0.7670 0.8152 0.9090 0.0023 
9.6 0.0416 0.6104 0.0005 0.5888 1.448 0.6860 0.0007 0.5963 0.8923 0.8289 0.0011 
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5. CONCLUSIONS AND RECOMMENDATIONS 
It is always a fact that the encapsulation efficiency, loading capacity, and drug 
release behavior are the most important issues for drug delivery systems. We suggest 
an alternative solution to solve the problems and these are using spray dryer to 
reduce particle diameter, to obtain narrow particle size distribution and to produce 
blends made by ternary polymer mixture to get best performance from the 
encapsulation material. In the core of the study, encapsulation materials are changed 
and effects on loading, release and release behavior are investigated.  
To make a clear comparison of all experimental results, different parts of the study is 
listed below. Table 5.1 shows drying results and differences between PCL-PEG-CH, 
PCL-PEG-CS, and PCL-PEG-SA microspheres. 
Table 5.1 : Comparison of drying studies. 
 
Temperature 
(
o
C) 
Flow rate 
(ml/min) 
Particle Size 
(µm) 
Surface 
Area (m
2
) 
Efficiency 
(wt%) 
PCL-PEG-CH 120 3 19.143±0.023 0.897 54.73 
PCL-PEG-CS 135 3 27.540±0.656 0.512 41.42 
PCL-PEG-SA 120 9 37.924±0.416 0.416 30.10 
      
Due to the Table 5.1, using of PCL-PEG-CH polymer mixture in a spray dryer is 
more effective to produce microspheres. Low particle size and high surface area is 
one of the most important features for an encapsulation material and PCL-PEG-CH 
microspheres are more advantageous than PCL-PEG-CS and PCL-PEG-SA 
microspheres. On the other hand, low agglomeration and loss in drying chamber of 
PCL-PEG-CH microspheres result in higher efficiency than PCL-PEG-CS and PCL-
PEG-SA microspheres. 
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Table 5.2 indicates differences on drug loading studies for three different 
encapsulation materials.  
Table 5.2 : Comparison of drug loading studies. 
 
Operating Conditions 
Efficiency 
(wt%) 
Loading Rate 
(mg/ml) 
PCL-PEG-CH 25 
o
C, 200 rpm, 2h 99.13±1.00 0.5/1.0 
PCL-PEG-CS 25 
o
C, 200 rpm, 1h 84.05±1.50 1.0/1.0 
PCL-PEG-SA 25 
o
C, 200 rpm, 1h 82.57±2.68 0.5/1.0 
    
L-ascorbic acid loading has reached saturation point about 1 hour for PCL-PEG-CS 
and PCL-PEG-SA microspheres; besides, it is a little bit longer (2 hours) for PCL-
PEG-CH. After peak points, loading rates of L-ascorbic acid is stabilized for all 
microspheres because loading capacity of microspheres are reached. On the other 
hand, because of the lowest particle size and the highest surface area, L-ascorbic acid 
loading ratio is higher in PCL-PEG-CH microsphere than the others. Furthermore, 
highly porous structure of chitosan polymer provides high loading rates for PCL-
PEG-CH microspheres. By this feature of PCL-PEG-CH microspheres, it also 
reduces loading rates for per microsphere to drug solution.  
Table 5.3 : Comparison of drug release studies. 
 
Efficiency (wt%) Time (h) 
PCL-PEG-CH 
pH 2.8: 93.18±3.0 
pH 7.4: 85.11±2.0 
pH 9.6: 67.71±3.0 
2 
2 
2 
PCL-PEG-CS 
pH 2.8: 23.68±3.36 
pH 7.4: 26.62±3.50 
pH 9.6: 68.92±5.70 
6 
8 
8 
PCL-PEG-SA 
pH 2.8: 22.91±4.35 
pH 7.4: 34.27±3.23 
pH 9.6: 26.49±1.41 
6 
6 
6 
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Drug release rates differences between microspheres and release mediums are listed 
in Table 5.3 and also in Figure 5.1. Results showed that drug release rates can be 
easily adjusted by changing structure of encapsulation material. The residence time 
of L-ascorbic acid drug in body depends on dissolution of the polymeric network and 
we achieved different drug residence time by changing encapsulation materials. 
Increasing of dissolution of encapsulation materials increased drug release rates into 
the release mediums. By this way, L-ascorbic acid release rates and release medium 
are manipulated.  
Table 5.4 simulates n values and drug release behavior of microspheres. 
Table 5.4 : Comparison of release kinetics and release behaviors. 
 
"n" value Release Behavior 
PCL-PEG-CH 
pH 2.8: 1.0008 
pH 7.4: 1.1577 
pH 9.6: 1.2475 
Super Case-II Transport 
Super Case-II Transport 
Super Case-II Transport 
PCL-PEG-CS 
pH 2.8: 0.2588 
pH 7.4: 0.4960 
pH 9.6: 0.5526 
Fickian Diffusion 
Anomalous Transport 
Anomalous Transport 
PCL-PEG-SA 
pH 2.8: 1.1075 
pH 7.4: 0.8152 
pH 9.6: 0.8923 
Super Case-II Transport 
Anomalous Transport 
Super Case-II Transport 
The results showed that L-ascorbic acid release is generally governed by non-Fickian 
diffusion, the dominant mechanism for drug transport is due to polymer relaxation 
and it means structure of microspheres resulted dissolution in the release medium.  
Drug release refers to the process in which drug solutes migrate from the initial 
position in the polymeric system to the polymer’s outer surface and then to the 
release medium [156]. This seemingly simple process is affected by multiple 
complex factors such as the physicochemical properties of the solutes, the structural 
characteristics of the material system, release environment, and the possible 
interactions between these factors. We chosen to change material matrix, so release 
kinetics and rates are dramatically changed at different release mediums.  
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Figure 5.1 : Comparison of drug release studies (a) Release in pH 2.8 (b) Release in pH 7.4 (c) Release in pH 9.6. 
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Several pharmaceutical products based on biodegradable delivery systems have been 
approved by the FDA, including hormones, anti-tumor drugs and antibiotics [157]. In 
general, biodegradable polymers contain labile bonds such as ester, amide, and 
anhydride bonds that are prone to hydrolysis or enzymatic degradation. PCL, PEG, 
CH, CS and SA are biodegradable and biocompatible polymers that we used to 
produce microspheres. By this way, toxic effect of encapsulation materials in body 
after and/or during drug release will be eliminated.  
L-ascorbic acid (vitamin C) an antioxidant which protects the body against 
oxidative stress. Oxidation reactions produce free radicals which can start chain 
reactions that damage cells, so it slows down the conversion of irritants into cancer-
causing substances. On the other hand, L-ascorbic acid has many benefits for body 
such as it involved in the production of collagen; it plays a significant role in the 
healing of wounds, cuts and grazes; individuals with adequate levels of vitamin C are 
thought to be better able to fight off infections compared to people with vitamin C 
deficiency [158]. We used L-ascorbic acid (vitamin C) as an active ingredient in our 
study because in the rapidly expanding market of dietary supplements, it is possible 
to find L-ascorbic acid in many different forms with many claims regarding its 
efficacy or bioavailability. However, L-ascorbic acid drugs or supplements are exist 
as mineral ascorbates are more likely to be found in combination with other mineral 
ascorbates, such as sodium ascorbates, calcium ascorbates, potassium ascorbates etc. 
When mineral salts of ascorbic acid are taken, both the ascorbic acid and the mineral 
appear to be well absorbed, so it is important to consider the dose of the mineral 
accompanying the ascorbic acid when taking large doses of mineral ascorbates. 
Unfortunately, taking large doses of mineral ascorbates causes accumulation of lots 
of minerals into the kidneys and finally, it results kidney stone. This problem is 
solved by producing of polymeric encapsulation materials. PCL, PEG, CH, CS and 
SA are biodegradable polymers and they do not provoke accumulation in kidneys or 
any other organ in a body.    
The current study investigates the fabrication of L-ascorbic acid drugs by 
microspheres for advanced spray-drying applications. In comparison the spray dryer 
method to others, we obtained much more uniform microspheres and lower particle 
diameters. Significantly, the experimental results indicate that to obtain particle 
diameters (19.143±0.023 µm with 0.897 m2/g surface area for PCL-PEG-CH; 
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27.540±0.656 µm with 0.512 m2/g surface area for PCL-PEG-CS; 37.924±0.416 µm 
with 0.416 m
2
/g surface area for PCL-PEG-SA) does not need to any additive effects 
during drying process. Furthermore, the microspheres can be straightforwardly 
transformed into the L-ascorbic acid loaded drugs. The dissolution rates of the drugs 
from microspheres are clearly improved at low, high or nearly neutral pH values by 
changing encapsulation materials. The shift of the mechanism from diffusion 
controlled to an anomalous transport changing the pH of the medium from acidic to 
basic conditions as seen drug release kinetic studies. It is also indicated that drug 
release ratio can be adjustable by this way, thus preventing the drug release until the 
target has been achieved. Towards the aim of the study, improving the vitamin C 
drugs, our method provides easily procurable and effective solution. 
Because of unstable and very sensitive L-ascorbic acid, producing vitamin C drugs 
are difficult. However, another significant result of our study is achieving 93.18% 
(the highest level) L-ascorbic acid release in 2 hours.   
We achieved the aim of the study by production of a stable and very effective L-
ascorbic acid loaded drug using biodegradable polymer solutions by spray dryer. By 
production of porous and high surface area microspheres, we succeeded higher drug 
loading and drug release efficiency in our study.  
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